



14th European LUPUS Meeting

19 - 22 MARCH 2024
BRUGES, BELGIUM

PROGRAMME



Download the LUPUS 2024 App!

Available in the App store and the Google Play store



Scan to download



- Committees 4
- Welcome Address 5
- Floor Plans of the Venue 6
- Programme at a Glance
 - Tuesday 19 March 8
 - Wednesday 20 March 9
 - Thursday 21 March 10
 - Friday 22 March 12
- Scientific Programme
 - Tuesday 19 March 13
 - Wednesday 20 March 14
 - Thursday 21 March 23
 - Friday 22 March 31
- Poster List
 - Poster Session 1 36
 - Poster Session 2 46
- Scientific Information 59
 - What are Fishbowls? 64
- Sponsored Sessions 65
- Sponsors & Exhibitors 81
- Social Programme 85
- Registration Information 89
- General Information 93

Congress Chairs

Nathalie Costedoat-Chalumeau, Paris (FR)
Frédéric Houssiau, Brussels (BE)

Local Scientific Committee

Alain Cornet, Brussels (BE)
Véronique Le Guern, Paris (FR)
Christina Duesing, Düsseldorf (DE)
Farah Tamirou, Brussels (BE)

International Scientific Committee

Nancy Agmon-Levin, Tel-Hashomer (IL)	Chandra Mohan, Houston (US)
Marta Alarcon-Riquelme, Granada (ES)	Eric Morand, Melbourne (AU)
Zahir Amoura, Paris (FR)	Marta Mosca, Pisa (IT)
Jeanette Andersen, Lupus Europe (DK)	Daniel G. Oliveira, Porto (PT)
Hans-Joachim Anders, München (DE)	Ioannis Parodis, Stockholm (SE)
Martin Aringer, Dresden (DE)	Michelle Petri, Baltimore (US)
Laurent Arnaud, Strasbourg (FR)	Bernardo Pons-Estel, Rosario (AR)
Sang-Cheol Bae, Seoul (KR)	Ida Povilaite, Lupus Europe (LT)
George Bertsias, Heraklion (GR)	Anisur Rahman, London (UK)
Patrick Blanco, Bordeaux (FR)	Lars Rönnblom, Uppsala (SE)
Dimitrios Boumpas, Athens (GR)	Brad Rovin, Columbus (US)
Marina Botto, London (UK)	Guillermo Ruiz-Irastorza, Bizkaia (ES)
Ian Bruce, Manchester (UK)	Jane Salmon, New York (US)
Jill Buyon, New York (US)	Lucy Scarle, Lupus Europe (UK)
Ricard Cervera, Barcelona (ES)	Georg Schett, Erlangen (DE)
Eric Daugas, Paris (FR)	Matthias Schneider, Düsseldorf (DE)
Anne Davidson, New York (US)	Nan Shen, Shanghai (CN)
David D'Cruz, London (UK)	Luís Sousa Inês, Coimbra (PT)
Andrea Doria, Padua (IT)	Elisabet Svenungsson, Stockholm (SE)
Thomas Dörner, Berlin (DE)	Maria Tektonidou, Athens (GR)
Antoine Enfrein, Nantes (FR)	Angela Tincani, Brescia (IT)
Rebecca Fischer-Betz, Düsseldorf (DE)	Dalila Tremarias, Lupus Europe (UK)
Richard Furie, New York (USA)	Ronald van Vollenhoven, Amsterdam (NL)
Martin Herrmann, Erlangen (DE)	Carlos Vasconcelos, Porto (PT)
David Isenberg, London (UK)	Carola Vinuesa, London (UK)
Ana Malvar, Buenos Aires (AR)	Alexandre Voskuyl, Amsterdam (NL)
Xavier Mariette, Paris (FR)	Tim Vyse, London (UK)

Organising Secretariat

Medicongress Services NV
Noorwegenstraat 49
9940 Evergem, Belgium
Phone: +32 (0) 9 218 85 85
lupus@medicongress.com
www.lupus24.be

Message from the Congress Chairs

Together with the International Scientific Committee members, we extend a warm welcome to the **14th European Lupus Meeting!**

The congress intends to share the latest clinical and basic advances in the field of systemic lupus erythematosus.

Our programme, developed in collaboration with patient representatives, features concurrent sessions that blend invited talks and oral abstract presentations, including a stimulating Great Debate and engaging Fishbowls sessions aimed at fostering interactions among participants, as well as sessions dedicated to patients and nurses.

Internationally renowned experts have been invited to share their expertise, thus providing a unique opportunity for both basic and clinical researchers to discuss their new data while enjoying the picturesque surroundings of Bruges.





The 14th European Lupus Meeting promises to be a memorable occasion, providing not only a forum for intellectual exchange but also a chance to reconnect with old friends and forge new connections.

Our sincere gratitude goes out to all committee members, invited faculty, Lupus Europe, exhibitors and participants, whose contributions make this event possible.

Enjoy the 14th European Lupus Meeting!



Frédéric Houssiau & Nathalie Costedoat-Chalumeau
Congress Chairs



Tuesday 19 March

Timing	Concert Hall
18.00 - 18.10	Welcome
18.10 - 19.10	Opening Lectures
19.10 - 19.45	Festive Opening of the 14th European Lupus Meeting
19.45 - 22.00	Walking Dinner in the Foyer (level 1) and 1st Balcony (level 2)

Wednesday 20 March

Timing	Concert Hall	Chamber Music Room	Studio 1
08.00 - 09.00		Industry-Sponsored Meeting	
09.00 - 10.30	Session 1: Drug Use in Real Life	Session 2: Genetics	
10.30 - 11.00	Coffee Break (level 1 & 2)		
11.00 - 12.30	Session 3: Pregnancy	Session 4: Classification & Subsets	
12.30 - 13.30	Lunch (level 1 & 2) & Poster Session 1 (12.45 hrs on level 3)		
13.30 - 14.30	Industry-Sponsored Symposium		
14.30 - 16.00	Session 5: Targeted Therapies	Session 6: Clinical Manifestations	Session 7: Best Approaches to manage Risks
16.00 - 16.30	Coffee Break (level 1 & 2)		
16.30 - 18.00	Session 8: Outcome Measures	Session 9: Pathophysiology of Lupus Nephritis	
18.00 - 19.30	Guided Visit of the City		

Thursday 21 March

Timing	Concert Hall	Chamber Music Room	Studio 1
08.00 - 09.00		Industry-Sponsored Meeting	Industry-Sponsored Meeting
09.00 - 10.30	Session 10: Damage	Session 11: Interferons and Innate Immunity	
10.30 - 11.00	Coffee Break (level 1 & 2)		
11.00 - 12.30	Session 12: Future Therapies	Session 13: Antiphospholipid Syndrome	Session 14: Lupus in Minorities
12.30 - 13.30	Lunch (level 1 & 2) & Poster Session 2 (12.45 hrs on level 3)		
13.30 - 14.30	Industry-Sponsored Symposium		
14.30 - 16.00	Session 15: Treatment of Nephritis I	Session 16: What really matters for Patients?	
16.00 - 16.30	Coffee Break (level 1 & 2)		
16.30 - 17.15	Fishbowls I - IV		
17.15 - 18.00	Fishbowls V - VIII		
19.30 - 23.00	Gala Dinner at Brewery 'De Halve Maan'		

Thursday 21 March: Fishbowl Sessions

Timing	Chamber Music Room	Studio 1	Green Room	Angel Room
16.30 - 17.15	Fishbowl I: When is the window of opportunity for disease modification in Lupus?	Fishbowl II: How is patient-centred care best organised by a lupus team?	Fishbowl III: How can medication adherence be improved?	Fishbowl IV: SLE/APS: When to stop treatment?
17.15 - 18.00	Fishbowl V: Glucocorticoids: Tapering to zero?	Fishbowl VI: What is the optimal management of fatigue?	Fishbowl VII: Pregnancy follow-up: How much is needed?	Fishbowl VIII: How should the lupus community work together to get the best (but not the worst) out of Chat GPT?

Friday 22 March

Timing	Concert Hall	Chamber Music Room
07.45 - 08.45		SLEuro General Assembly
08.45 - 09.15	Industry-Sponsored Symposium	
09.15 - 10.35	Session 17: Treatment of Nephritis II	Session 18: Pathophysiology
10.35 - 11.00	Coffee Break (level 1 & 2)	
11.00 - 11.30	Industry-Sponsored Symposium	
11.30 - 12.30	Great Debate	
12.30 - 12.45	Closing Ceremony	
12.45 - 13.30	Light Lunch (level 1 & 2)	

16.00 Registration

Opening Ceremony & Opening Lectures

Concert Hall

- 18.00 **Welcome**
Frédéric Houssiau & Nathalie Costedoat-Chalumeau
Congress Chairs
- 18.10 **I1** **What have been the major achievements in the field of lupus within the last decade and what is next?**
Eric Morand, Melbourne (AU)
- 18.40 **I2** **Improving communication between lupus patients and physicians**
Lucy Scarle, Lupus Europe
- 19.10 **Festive Opening of the 14th European Lupus Meeting**
- 19.45 **Walking Dinner in the Foyer (level 1) and 1st Balcony (level 2)**

08.00 Industry-Sponsored Breakfast Meeting (see page 68)

Parallel Sessions 1 & 2

Session 1: Drug use in Real Life

Chairs: Michelle Petri (USA) & Guillermo Ruiz-Irastorza (ES)

Concert Hall

- 09.00 I3 **Hydroxychloroquine: What's new?**
Nathalie Costedoat-Chalumeau, Paris (FR)
- 09.20 I4 **Strategies to minimize glucocorticoids exposure**
Zahir Amoura, Paris (FR)
- 09.40 I5 **Biologics in real life**
Alexandre Voskuyl, Amsterdam (NL)
- 10.00 O1 **Impact of intravenous belimumab treatment on steroid use and disease activity in patients with systemic lupus erythematosus (SLE) in the US in clinical practice: 24-month results from the OBSERVE study**
Daniel Moldaver¹, Seth Anderson², Marguerite Bracher³, Roger A. Levy⁴, Holly A. Quasny⁵, Robert Wood⁶, Rosie Wild⁶, Alexandra Cusmano^{6*}, Elke Rottier⁶ (¹Canada, ^{2,4,5}USA, ^{3,6}UK)
- 10.10 O2 **Serious infection, including severe COVID19, seems not to be a major clinical problem in patients with systemic lupus erythematosus treated with belimumab, according to the data from a large multicenter cohort**
Iñigo Rúa-Figueroa, Irene Altabás González, Norman Jiménez Otero, Judit Font Urgelles, Ivette Casafont Sole, Marta De la Rubia Navarro, José Andrés Roman Ivorra, Andrea Hernández-Martín, María Galindo Izquierdo, Tarek Salman Montes, Javier Narváez, Paola Vidal-Montal, María Jesús García Villanueva, María Ángeles Blázquez Cañamero, Carlos Marras Fernández, María Piqueras García, Julia Martínez Barrio, Marina Sánchez Lucas, Josefina Cortés Hernández, Eleonora Penzo, Jaime Calvo Alen, Margarida Vasques Rocha, Eva Tomero, Raúl Menor Almagro, Myriam Gandía Martínez, José A. Gómez-Puerta, Beatriz Frade-Sosa, Consuelo Ramos Giráldez, Carmen Trapero Pérez, Elvira Díez Álvarez, Clara Moriano, Alejandro Muñoz Jiménez, José María Pego Reigosa (Spain)
- 10.20 O3 **Physician experience influences glucocorticoid prescribing patterns in systemic lupus erythematosus (SLE): Results from the LUPHPOS survey**
Cristiana Sieiro Santos¹, Sarah Dyball², Kunal Chandwar³, Elisabetta Chessa⁴, Marta Mosca⁵ (¹Spain, ²UK, ³India, ^{4,5}Italy)
- 10.30 Coffee Break (level 1 & 2) and Poster Viewing (level 3)

08.00 Industry-Sponsored Breakfast Meeting (see page 68)

Session 2: Genetics

Chairs: Marta Alarcon-Riquelme, Granada (ES) & Lars Rönnblom (SE)

Chamber Music Room

- 09.00 I6 **Cross ancestry analysis**
Tim Vyse, London (UK)
- 09.20 I7 **SLE genetics update and clinical implication**
Sang-Cheol Bae, Seoul (KR)
- 09.40 I8 **Gender Bias**
George Bertias, Heraklion (GR)
- 10.00 O4 **Clinical characteristics of patients with high SLE-specific and high multitrait polygenic risk – An investigation of SLE risk loci**
Nina Oparina¹, Sarah Reid¹, Ahmed Sayadi¹, Maija-Leena Eloranta¹, Martina Frodlund², Karoline Lerang³, Andreas Jönsen⁴, Solbritt Rantapää-Dahlqvist⁵, Anders A. Bengtsson⁴, Anna Rudin⁶, Øyvind Molberg³, Christopher Sjöwall², Lars Rönnblom¹, Dag Leonard¹ (^{1,2,4,5,6}Sweden, ³Norway)
- 10.10 O5 **Exploring the impact of genome-wide DNA methylation alterations on chromosome X inactivation and female lupus**
Olivia Castellini-Pérez¹, Elena Povedano-Espejo^{1,2}, Guillermo Barturen^{1,3}, Abir Azri^{1,4}, Ruth Dominguez¹, Marta E. Alarcón-Riquelme¹, Elena Carnero-Montoro^{1,3} (^{1,3}Spain, ⁴Tunisia)
- 10.20 O6 **Epidemiology of moderate-to-severe SLE in Sweden**
Martina Frodlund¹, Dag Leonard², Thomas Haugli-Stephens³, Lauren Remkus⁴, Daniel Eek⁵, Fabian Söderdahl⁶, Andreas Jönsen⁷ (^{1,2}: ^{5,7}Sweden, ³Norway, ⁴Denmark)
- 10.30 Coffee Break (level 1 & 2) and Poster Viewing (level 3)

Parallel Sessions 3 & 4

Session 3: Pregnancy

Chairs: Veronique Le Guern (FR) & Jane Salmon (US)

Concert Hall

- 11.00 **I9** **Updates from the bench and bedside in neonatal lupus**
Jill Buyon, New York (US)
- 11.20 **I10** **Safety of new lupus drugs before and during pregnancy**
Rebecca Fischer-Betz, Düsseldorf (DE)
- 11.40 **I11** **What is still unclear in lupus pregnancy?**
Angela Tincani, Brescia (IT)
- 12.00 **O7** **High incidence of both spontaneous and indicated preterm birth in women with systemic lupus erythematosus: A systematic review and meta-analysis**
Birgit Blomjous¹, Carolien Abheiden², Ciska Slaager³, Anadeijda Landman¹, Johannes Ket⁴, Jane Salmon⁵, Jill Buyon⁶, Martijn Heymans⁷, Johanna de Vries², Irene Bultink¹, Marjon de Boer^{2 (1-4: 7The Netherlands; 5-6USA)}
- 12.10 **O8** **Hydroxychloroquine blood levels at first trimester of pregnancy and materno-fetal outcomes: A prospective study of 174 patients with systemic lupus erythematosus (GR2 study)**
Gelsomina Alle^{1,2}, Gaëlle Guettrot-Imbert¹, Estibaliz Lazaro³, Anna Molto^{1,4}, Maddalena Larosa⁵, Anne Murarasu¹, Christophe Richez⁶, Nathalie Morel¹, Pauline Orquevaux⁷, Laurent Sailler⁸, Viviane Queyre⁹, Benoit Blanchet¹⁰, Emmanuelle Pannier¹, Luc Mouthon^{1,12}, Véronique Le Guern¹, Nathalie Costedoat-Chalumeau^{1,12}, on behalf of the GR2 Study Group (1: 3-4: 6-12France, 2Argentina, 5Italy)
- 12.20 **O9** **Early pregnancy exposure to hydroxychloroquine and preterm delivery in systemic lupus erythematosus**
Ngoc V. Nguyen¹, Annica Dominicus¹, Anna Sandström^{1,2}, Elisabet Svenungsson³, Elizabeth V. Arkema¹, Julia F. Simard^{1,4 (1-3Sweden, 4USA)}
- 12.30 Lunch (level 1 & 2)
- 12.45 **Poster Session I (level 3)** **2nd Balcony**
- 13.30 **Industry-Sponsored Symposium (see page 69)** **Concert Hall**

Session 4: Classification and Subsets

Chairs: Ian Bruce (UK) & Andrea Doria (IT)

Chamber Music Room

- 11.00 **I12** **EULAR/ACR SLE classification criteria: 5 years later**
Martin Aringer, Dresden (DE)
- 11.20 **I13** **Subgrouping SLE patients: Is this the way forward?**
Elisabeth Svenungsson, Stockholm (SE)
- 11.40 **I14** **Use of molecular stratification to identify (non)-responders**
Marta Alarcon-Riquelme, Granada (ES)
- 12.00 **O10** **Ischemic stroke subtypes in SLE - Associations with a STAT4 risk genotype**
Liisa Hopia, Anna Laveskog, Andreas Jönsen, Dag Leonard, Johanna T. Gustafsson, Iva Gunnarsson, Agneta Zickert, Gunnel Nordmark, Anders A. Bengtsson, Kerstin Elvin, Johanna K. Sandling, Ann-Christine Syvänen, Lars Rönnblom, Magnus Andersson, Elisabet Svenungsson (Sweden)
- 12.10 **O11** **Unsupervised machine-learning identifies distinct clusters based on B cell phenotyping and autoantibody profiles in patients with systemic lupus erythematosus**
Mariele Gatto¹, Roberto Depascale², Nursen Cetrez³, Julius Lindblom³, Dionysis Nikolopoulos³, Andrea Doria², Ioannis Parodis^{3,4,5 (1-2Italy, 3Sweden)}
- 12.20 **O12** **Immune complexes containing anti-dsDNA in patients with systemic lupus erythematosus with renal involvement - Association with renal activity and response to treatment**
Iva Gunnarsson, Agneta Zickert, Azita Sohrabian, Enrico Fuzzi, Elisabet Svenungsson, Johan Rönnelid (Sweden)
- 12.30 Lunch (level 1 & 2)
- 12.45 **Poster Session I (level 3)** **2nd Balcony**
- 13.30 **Industry-Sponsored Symposium (see page 69)** **Concert Hall**

Parallel Sessions 5, 6 & 7

Session 5: Targeted Therapies

Chairs: Eric Morand (Au) & Ioannis Parodis (SE)

Concert Hall

- 14.30 **I15** **Targeting Type I IFN in SLE and lupus nephritis**
Richard Furie, New York (US)
- 14.50 **I16** **Targeting B cell lineage cells in SLE: From today's experience towards future possibilities**
Thomas Dörner, Berlin (DE)
- 15.10 **I17** **Choosing wisely. Which biological should we use in which patient?**
Ronald van Vollenhoven, Amsterdam (NL)
- 15.30 **O13** **Innate immunity transcriptional profiles as potential predictive biomarkers for treatment response in systemic lupus erythematosus: Insights from a longitudinal study**
Panagiotis Garantziotis^{1,2}, Georgia-Savina Moysidou¹, Stavros Doumas³, Dionysis Nikolopoulos¹, George Sentis¹, Ricardo Grieshaber-Bouyer², Myrto Nikoloudaki⁴, Dimitra Nikoleri⁴, Styliani Polia⁴, Anastasia Filia⁴, Antonis Fanouriakis¹, George Bertias⁴, Dimitrios T. Boumpas¹ (¹Greece, ^{2,4}Germany, ³USA)
- 15.40 **O14** **Rituximab Objective Outcome measures Trial in SLE (ROOTS): Outcomes of randomised and rescue rituximab therapy in a double-blind randomised placebo-controlled trial**
Khaled Mahmoud, Michelle Wilson, Yuzaiful Yusof, Sarah Brown, Elizabeth M. Hensor, Edward M. Vital (UK)
- 15.50 **O15** **B cell, T cell, cytotoxic/NK cell, and mitochondrial gene dysregulation patterns separate neuropsychiatric systemic lupus erythematosus patients into two distinct subgroups with differential anticipated response to targeted therapies**
Julius Lindblom¹, Dionysis Nikolopoulos¹, Daniel Toro-Domínguez², Elena Carnero-Montoro², Maria Orietta Borghi^{3,4}, Jessica Castillo⁵, Ellen Iacobaeus⁶, Yvonne Enman¹, PRECISESADS Clinical Consortium, Chandra Mohan⁵, Lorenzo Beretta⁷, Marta E. Alarcón-Riquelme^{2,8}, Guillermo Barturen^{2,9}, Ioannis Parodis^{1,10} (^{1,6,8,10}Sweden, ^{2,9}Spain, ^{3-4,7}Italy, ⁵USA)
- 16.00 **Coffee Break (level 1 & 2) and Poster Viewing (level 3)**

Session 6: Clinical Manifestations

Chairs: Angela Tincani (IT) & David D'Cruz (UK)

Chamber Music Room

- 14.30 **I18** **Lupus enteritis**
David D'Cruz, London (UK)
- 14.50 **I19** **Autoinflammatory manifestations in SLE**
Carlos Vasconcelos, Porto (PT)
- 15.10 **I20** **Early events in neuropsychiatric lupus**
Dimitri Boumpas, Athens (GR)
- 15.30 **O16** **pQTL analysis of ficolin-3 activity reveals a link between the lectin pathway of complement and hematological disease manifestations in systemic lupus erythematosus**
Linnea Lindelöf¹, Solbritt Rantapää-Dahlqvist², Christian Lundtoft³, Johanna K. Sandling³, Dag Leonard³, Ahmed Sayadi³, Lars Rönnblom³, Helena Enocsson⁴, Christopher Sjöwall⁴, Andreas Jönsen⁵, Anders A. Bengtsson⁵, Mun-Gwan Hong⁶, Lina-Marcela Diaz-Gallo⁷, Matteo Bianchi⁸, Sergey V. Kozyrev⁸, Kerstin Lindblad-Toh^{8,9}, the DISSECT consortium, the ImmunoArray consortium, Kristina Nilsson Ekdahl^{1,10}, Bo Nilsson¹, Iva Gunnarsson⁷, Elisabet Svenungsson⁷, Oskar Eriksson¹ (^{1-8,10}Sweden, ⁹USA)
- 15.40 **O17** **SLESIS-R: An improved score for prediction of serious infection in patients with systemic lupus erythematosus, developed from RELESSER prospective database cohort**
Iñigo Rúa-Figueroa, María Jesus García de Yébenes, Julia Martínez-Barrio, María Galindo-Izquierdo, Jaime Calvo-Alén, Antonio Fernández-Nebro, Raúl Menor-Almagro, Loreto Carmona, Beatriz García-Tejera, Eva Tomero, Mercedes Freire, Clara Sanguesa, Loreto Horcada, Ricardo Blanco, Esther Uriarte Isacelaya, Javier Narváez, José Rosas, Silvia Gómez Sabater, Clara Moriano, José Luis Andrés, Vicenç Torrente Segarra, Elena Aurrecoechea, Ana Pérez Gómez, Francisco J. Nóvoa, Eva Salgado Pérez, Nuria Lozano-Rivas, Carlos Montilla-Morales, Esther Ruiz-Lucea, Marta Arévalo, Carlota Iniguez, María J. García Villanueva, Lorena Expósito, Monica Ibañez, Gema Bonilla Hernán, Irene Carrión Bárbera, Celia Eraudquin, Jorge Fragío, Angela Pecondon-Español, Francisco Javier Toyos, Tatiana Cobo, Alejandro Muñoz-Jimenez, José Eloy Oller, José M. Pego-Reigosa (Spain)
- 15.50 **O18** **Data-driven clustering of cerebrospinal fluid proteome reflects clinical phenotypes of systemic lupus erythematosus**
Elsa Grenmyr, Kristoffer Zervides, Seyed Morteza Najibi, Birgitta Gullstrand, Charlotte Welinder, Jessika Nystedt, Petra C. Nilsson, Pia C. Sundgren, Robin Kahn, Andreas Jönsen, Anders A. Bengtsson (Sweden)
- 16.00 **Coffee Break (level 1 & 2) and Poster Viewing (level 3)**

Session 7: Best Approaches to manage Risks*In partnership with Lupus Europe patient organisation*

Chairs: Marta Mosca (IT) & Kikka Myllis (FI)

- 14.30 **I21** **Hydroxychloroquine**
Nathalie Costedoat-Chalumeau, Paris (FR)
- 14.55 **I22** **Managing cardiovascular risk**
Christina Duesing, Düsseldorf (DE)
- 15.20 **I23** **Pregnancy with lupus**
Farah Tamirou, Brussels (BE)
- 15.45 **O19** **ChatSLE - Consulting ChatGPT for 100 frequently asked lupus questions**
Isabell Haase, Tingting Xiong, Julia Greenfield, Johannes Knitza, Martin Krusche (Germany)
- 16.00 **Coffee Break (level 1 & 2) and Poster Viewing (level 3)**

Studio 1**Parallel Sessions 8 & 9****Session 8: Outcome Measures**

Chairs: Anisur Rahman (UK) & Martin Aringer (DE)

Concert Hall

- 16.30 **I24** **Defining the targets: Where do we stand?**
Andrea Doria, Padua (IT)
- 16.50 **I25** **Which is the optimal primary endpoint for lupus clinical trials?**
Luís Sousa Inês, Coimbra (PT)
- 17.10 **I26** **Ten tips for managing difficult lupus**
Guillermo Ruiz-Irastorza, Bizkaia (ES)
- 17.30 **O20** **Lupus low disease activity state and organ damage in relation to quality of life in SLE: A cohort study with up to 11 years of follow-up**
Ioannis Parodis, Thomas Stephens, Annica Dominicus, Daniel Eek, Christopher Sjöwall (Sweden)
- 17.40 **O21** **Is SLE-DAS better than BILAG-2004 to identify severe SLE disease activity? Post-hoc analysis of 438 SLE patients from the anifrolumab clinical trials**
Diogo Jesus^{1,2}, Carla Henriques^{3,4}, Ana Matos^{3,5}, Andrea Doria⁶, Luís Sousa Inês^{2,7} (^{1-5,7}Portugal, ⁶Italy)
- 17.50 **O22** **Factors associated with SLE patient concordance to medication - Does nurse initiated therapy make a difference?**
Rosaria Salerno, Sasha Saadia Ali, Flora Dell'Accio, Heather Lapham, Jo Dobson, Patrick Gordon, Chris Wincup (UK)
- 18.00 **End of Day 1 and Guided Visit of the City**

Session 9: Pathophysiology of Lupus Nephritis
Chamber Music Room

Chairs: Anne Davidson (USA) & George Bertias (GR)

- 16.30 **I27** **Cross species analysis of renal myeloid cells in lupus nephritis**
Anne Davidson, New York (US)
- 16.50 **I28** **Complement and kidney injury in lupus nephritis**
Brad Rovin, Columbus (US)
- 17.10 **I29** **OMICs insights on lupus nephritis chronicity**
Chandra Mohan, Houston (US)
- 17.30 **O23** **Interferon upregulation and B and plasma cell gene dysregulation patterns reveal three distinct lupus nephritis subgroups with differential anticipated response to targeted therapies**
Ioannis Parodis^{1,2}, Julius Lindblom¹, Daniel Toro-Domínguez³, Lorenzo Beretta⁴, Maria Orietta Borghi^{5,6}, Jessica Castillo⁷, Elena Carnero-Montoro³, Yvonne Enman¹, PRECISESADS Clinical Consortium, Chandra Mohan⁷, Marta E. Alarcón-Riquelme^{3,8}, Guillermo Barturen^{3,9}, Dionysis Nikolopoulos^{1(1-2:8)Sweden, 3:9Spain, 4-6Italy, 7USA)}
- 17.40 **O24** **APOL1 genotype is a major determinant of lupus nephritis severity in patients of African ancestry**
Carole Burger, Nicolas Benichou, Céline Narjoz, Nathalie Costedoat-Chalumeau, Véronique Le Guern, Aurélie Hummel, Noémie Jourde Chiche, Julie Chezel, Éric Thervet, Nicolas Pallet, Alexandre Karras (France)
- 17.50 **O25** **Lupus podocytopathy: A rare form of lupus nephritis - An Italian retrospective multicenter study**
Grazia Dea Bonelli, Savino Sciascia, Marta Calatroni, Vincenzo L'imperio, Francesco Reggiani, Roberta Fenoglio, Lorenza Argolini, Camillo Carrara, Nicola Lepori, Fausta Catapano, Mariele Gatto, Chiara Tani, Domenico Santoro, Maria Gerosa, Marta Mosca, Dario Roccatello, Renato Alberto Sinico, Gabriella Moroni (Italy)
- 18.00 **End of Day 1 and Guided Visit of the City**

 08.00 **Industry-Sponsored Breakfast Meetings** (see pages 73 - 75)

Parallel Sessions 10 & 11
Session 10: Damage
Concert Hall

Chairs: Matthias Schneider (DE) & Laurent Arnaud (FR)

- 09.00 **I30** **Cardiovascular risk in SLE and APLS**
Maria Tektonidou, Athens (GR)
- 09.20 **I31** **Working towards a new SLE damage index**
Ian Bruce, Manchester (UK)
- 09.40 **I32** **Long-term follow-up of the University College London cohort**
Anisur Rahman, London (UK)
- 10.00 **O26** **First investigation of the performance of validated cardiovascular risk scores in a global (UK/US) cohort of children, adolescents, and young adults with juvenile-onset systemic lupus erythematosus**
Yiming Gao¹, Misato Niwa¹, Junjie Peng², Stacy P. Ardoin³, Laura E. Schanberg⁴, Laura Lewandowski⁵, George Robinson², Elizabeth Jury⁶, Coziana Ciurtin^{2 (1-2:6UK, 3-5USA)}
- 10.10 **O27** **Metabolite signature predicts subclinical atherosclerosis in Systemic Lupus Erythematosus (SLE)**
Laurel Woodridge^{1,2}, Elvira Chocano Navarro¹, Lucia Martin-Guiterrez¹, George Robinson¹, Christine Orengo², Maria Tektonidou³, Anisur Rahman¹, Inés Pineda Torra⁴, Elizabeth C. Jury^{1 (1-2UK, 3Greece, 4Spain)}
- 10.20 **O28** **Unveiling the impact of neuropsychiatric involvement in systemic lupus erythematosus on damage accrual**
Dionysis Nikolopoulos, Nursen Cetrez, Julius Lindblom, Ioannis Parodis (Sweden)
- 10.30 **Coffee Break (level 1 & 2) and Poster Viewing (level 3)**

08.00 **Industry-Sponsored Breakfast Meetings** (see pages 73 - 75)

Session 11: Interferons and Innate Immunity **Chamber Music Room**

Chairs: Patrick Blanco (FR) & Alexandre Voskuyl (NL)

- 09.00 **I33** **Type I IFN and immunometabolism in SLE**
Marina Botto, London (UK)
- 09.20 **I34** **The genetics of the IFN system in SLE**
Lars Rönnblom, Uppsala (SE)
- 09.40 **I35** **Inborn errors of innate immunity that instigate human lupus**
Carola Vinuesa, London (UK)
- 10.00 **O29** **Gut epithelial barrier dysfunction in lupus triggers a differential humoral response against commensals**
María Botía-Sánchez¹, Georgina Galicia¹, Lorena Albaladejo-Maricó¹, Daniel Toro-Domínguez¹, Ana López¹, Abelardo Margolles², Marta E. Alarcón-Riquelme^{1,3} (^{1,2}Spain, ³Sweden)
- 10.10 **O30** **Anti-histone and anti-nucleosome rather than anti-dsDNA antibodies associate with IFN-induced biomarkers in Sudanese and Swedish SLE patients**
Sahwa Elbagir¹, NasrEldeen A. Mohammed², Vilija Oke^{3,4}, Anders Larsson⁵, Jan Nilsson⁶, Amir Elshafie^{1,7}, Elnour M. Elagib⁸, Musa A.M. Nur⁹, Iva Gunnarsson³, Elisabet Svenungsson³, Johan Rönnelid¹ (^{1,3,4,7}Sweden, ^{2,8-9}Sudan)
- 10.20 **LBO1** **DORIS remission in patients with SLE treated with anifrolumab or placebo during the 4-year TULIP-LTE trial: Post hoc analysis**
Ronald van Vollenhoven¹, Eric Morand², Richard Furie³, Kenneth Kalunian⁴, Raj Tummala⁵, Gabriel Abreu⁶, Hussein Al-Mossawi⁷, Catharina Lindholm⁶ (¹The Netherlands, ²Australia, ³⁻⁵USA, ⁶Sweden, ⁷UK)

10.30 **Coffee Break** (level 1 & 2) and **Poster Viewing** (level 3)

Parallel Sessions 12, 13 & 14

Session 12: Future Therapies

Chairs: Richard Furie (USA) & Ronald van Vollenhoven (NL)

Concert Hall

- 11.00 **I36** **CAR T cell therapy in autoimmune diseases**
Georg Schett, Erlangen (DE)
- 11.20 **I37** **JAK inhibitors**
Ian Bruce, Manchester (UK)
- 11.40 **I38** **Immuno-organoids: A new tool for testing new drugs in autoimmune diseases**
Xavier Mariette, Paris (FR)
- 12.00 **O31** **How useful are the mouse models of lupus for clinical research and drug testing?**
María Rivas-Torrubia¹, María Morell¹, Zuzanna Makowska², Jorge Kageyama², Anne Buttgeriet², PRECISEADS Cytometry Consortium, Ralf Lesche², Fiona McDonald², Marta E. Alarcón-Riquelme¹, Guillermo Barturen¹ (¹Spain, ²Germany)
- 12.10 **O32** **Impact of patient baseline characteristics on SLE Responder Index-4 (SRI[4]) responses to deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor in the phase 2 PAISLEY trial in systemic lupus erythematosus**
Eric Morand¹, Cristina Arriens², Laura Geraldino-Pardilla³, Ann E. Clarke⁴, Samantha Pomponi⁵, Coburn Hobar⁵, Thomas Wegman⁵, Ravi Koti⁶, Subhashis Banerjee⁵, Ronald van Vollenhoven⁷ (¹Australia, ^{2-3,5-6}USA, ⁴Canada, ⁷The Netherlands)
- 12.20 **O33** **Longitudinal assessment of biomarkers in NOBILITY, a randomized, phase II clinical trial of obinutuzumab for treatment of proliferative lupus nephritis**
Richard A. Furie¹, Sander W. Tas², Ana Malvar³, Cary M. Looney⁴, Harini Raghu⁵, Veronica G. Anania⁵, Ashley Mao⁶, Thomas Schindler⁴, Elsa Martins⁴, Jorge A. Ross Terres⁵, Edward M. Vital^{7,8} (^{1,5}USA, ²The Netherlands, ³Argentina, ⁴Switzerland, ⁶Canada, ^{7,8}UK)
- 12.30 **Lunch** (level 1 & 2)
- 12.45 **Poster Session II** (level 3) **2nd Balcony**
- 13.30 **Industry-Sponsored Symposium** (see page 76) **Concert Hall**

Chamber Music Room

Session 13: Antiphospholipid Syndrome

Chairs: Ricard Cervera (PT) & Maria Tektonidou (GR)

- 11.00 I39 **Management of refractory APS**
Ricard Cervera, Barcelona (ES)
- 11.20 I40 **Pregnancy in APS: New hopes on the horizon?**
Jane Salmon, New York (US)
- 11.40 I41 **Cardiac manifestations in APS**
Nancy Agmon-Levin, Tel-Hashomer (IL)
- 12.00 O34 **Plasma Thrombospondin-1 levels are associated with arterial and venous thrombotic events in systemic lupus erythematosus**
Marina Barguil Macedo¹, Iva Gunnarsson², Agneta Zickert², Elisabet Svenungsson², Christian Lood¹ (USA, ²Sweden)
- 12.10 O35 **Timing of thromboembolic events in systemic lupus erythematosus associated to Antiphospholipid Syndrome (PS); Results from a population-based study set in Norway**
Sigrid R. Moe, Hilde Haukeland, Torild Garen, Antonela Botea, Anniken Orre, Heidi Øvreås, Thea Bøe, Gro Å. Wivestad, Nenad Damjanic, Cathrine Brunborg, Sella A. Provan, Øyvind Molberg, Karoline Lerang (Norway)
- 12.20 LBO2 **Long-term renal and cardiovascular risks of tacrolimus in lupus nephritis patients**
Mieke van Schaik, Obbo W. Bredewold, Merel Priester, Wieneke M. Michels, Ton J. Rabelink, Joris I. Rotmans, Y.K. Onno Teng (The Netherlands)
- 12.30 Lunch (level 1 & 2)
- 12.45 **Poster Session II** (level 3) **2nd Balcony**
- 13.30 **Industry-Sponsored Symposium** (see page 76) **Concert Hall**

Studio 1

Session 14: Lupus in Minorities

In partnership with Lupus Europe patient organisation

Chairs: Bernardo Pons-Estel (AR) & Andreas Panteli (CH)

- 11.00 I42 **Ethnicity**
Antoine Enfrein, Nantes (FR)
- 11.30 I43 **Male with lupus**
George Bertias (GR)
- 11.50 I44 **Economically/socially less advantaged patients with lupus**
Daniel G. Oliveira, Porto (PT)
- 12.10 O36 **HPV vaccination and cervical screening in SLE patients**
Marya Khan, Sylvia Huang, Griffith Marchan, Ravindra Rajakariar, Andrea Cove-Smith, Angela Pakozdi, Myles Lewis, Malvina Cunningham, Kate Wiles, Debasish Pyne (UK)
- 12.20 O37 **Male gender, educational level, disease activity, prednisone daily dose and previous medical adherence are predictive of medical adherence in systemic lupus erythematosus patients - Data from the Almenara Lupus Cohort**
Manuel F. Ugarte-Gil^{1,2}, Rocío V. Gamboa-Cardenas^{1,2}, Victor Pimentel-Quiroz^{1,2}, Cristina Reategui-Sokolova^{1,3}, Claudia Elera-Fitzcarrald^{1,4}, Mariela Medina^{1,5}, Zoila Rodriguez-Bellido^{1,6}, Cesar Pastor-Asurza^{1,6}, Graciela S. Alarcón^{7,8} (¹⁻⁶Peru, ⁷USA)
- 12.30 Lunch (level 1 & 2)
- 12.45 **Poster Session II** (level 3) **2nd Balcony**
- 13.30 **Industry-Sponsored Symposium** (see page 76) **Concert Hall**

Parallel Sessions 15 & 16

Session 15: Treatment of Nephritis I

Chairs: Brad Rovin (USA) & Farah Tamirou (BE)

Concert Hall

- 14.30 **I45** **Treatment of lupus nephritis: Beyond recommendations**
Frédéric Houssiau, Brussels (BE)
- 14.50 **I46** **The long road to complete remission of lupus nephritis**
Ana Malvar, Buenos Aires (AR)
- 15.10 **I47** **Repeat kidney biopsy to guide treatment?**
Ioannis Parodis, Stockholm (SE)
- 15.30 **O38** **Persistence of urinary biomarkers of intrarenal inflammation precedes loss of kidney function in lupus nephritis**
Andrea Fava, Mohammed G. Atta, Jose Monroy Trujillo, Derek Fine, Daniel Goldman, Peter Izmirly, H. Michael Belmont, the Accelerating Medicines Partnership in RA/SLE, Jill Buyon, Michelle Petri (USA)
- 15.40 **O39** **Immune deposit resorption in per-protocol repeat kidney biopsy performed in patients with proliferative lupus nephritis**
Nursen Cetrez^{1,2}, Farah Tamirou³, Séverine Nieuwland³, Selda Aydin⁴, Ioannis Parodis^{1,2,5}, Frédéric A. Houssiau^{3 (1-2,5)Sweden, 3-4Belgium)}
- 15.50 **O40** **Impact of glucocorticoid dose on complete response, serious infections, and mortality during the initial therapy of lupus nephritis: A systematic review and meta-analysis of the standard of care arms of randomized controlled trials**
Gabriel Figueroa-Parra¹, María C. Cuéllar-Gutiérrez^{1,2}, Mariana González-Treviño¹, Alain Sanchez-Rodriguez¹, Jaime Flores-Gouyonnet¹, José A. Meade-Aguilar^{1,3}, Larry J. Prokop⁴, M. Hassan Murad⁵, María Dall'Era⁶, Brad H. Rovin⁷, Frédéric Houssiau⁸, Farah Tamirou⁹, Fernando C. Fervenza¹⁰, Cynthia S. Crowson¹¹, Michael S. Putman¹², Alí Duarte-García^{1 (1-3,7,10-12)USA, 2Chile, 8-9Belgium)}

16.00 Coffee Break (level 1 & 2) and Poster Viewing (level 3)

Session 16: What really matters for Patients?

In partnership with Lupus Europe patient organisation

Chairs: Jean-Charles Piette (FR) & Nuria Zúñiga (ES)

Chamber Music Room

- 14.30 **I48** **Management of fatigue**
Laurent Arnaud, Strasbourg (FR) & Ida Povilaite (Lupus Europe)
- 14.55 **I49** **Quality of life and disease burden**
Marta Mosca, Pisa (IT) & Dalila Tremarias (Lupus Europe)
- 15.20 **I50** **Shared decision making**
Matthias Schneider, Düsseldorf (DE) & Jeanette Andersen (Lupus Europe)
- 15.45 **O41** **Sexual dysfunction in women with systemic lupus erythematosus: A multicentre cross-sectional study**
Rita Pinheiro Torres^{1,2,3,4}, Maria Helena Lourenço^{1,2,3}, Santiago Rodrigues-Manica³, Vanessa Fraga⁵, Catarina Abreu⁵, Roberto Costa⁶, Carolina Matos⁶, Beatriz Mendes⁷, Beatriz Samões⁸, Inês Silva^{1,2}, Fernando M. Pimentel Santos^{1,2,3}, Manuela Costa^{1,3}, Jaime C. Branco^{1,2,3}, Alexandre Sepriano^{1,2,3 (1-3,5-8)Portugal, 4Sweden)}
- 15.55 **O42** **Patients with systemic lupus erythematosus experience poor health-related quality of life despite a low disease activity state or remission**
Ioannis Parodis^{1,2}, Julius Lindblom¹, Nursen Cetrez¹, Leonardo Palazzo¹, Henri Ala¹, Mandana Nikpour³, Adrian Levitsky¹, Vibeke Strand^{4 (1-2)Sweden, 3Australia, 4USA)}

16.05 Coffee Break (level 1 & 2) and Poster Viewing (level 3)

16.30 - 17.15 Fishbowls I - IV

- I Chamber Music Room**
When is the window of opportunity for disease modification in Lupus?
 Sponsored session – see page 77
- II Studio 1**
How is patient-centred care best organised by a lupus team?
 Chair: Daliya Pencheva (Sofia, BG)
 Discussants: Eric Morand (Melbourne, US), Luís Sousa Inês (Coimbra, PT), Elisabet Svenungsson (Stockholm, SE), Elfriede Wijmsma (Lupus Europe, NL)
- III Green Room**
How can medication adherence be improved?
 Chair: Emiliano Marasco (Rome, Italy)
 Discussants: Michelle Petri (Baltimore, US) Nathalie Costedoat-Chalumeau (Paris, FR), Guillermo Ruiz-Irastorza (Bizkaia, ES), Amy Somers (Lupus Europe, UK)
- IV Angel Room**
SLE/APS: When to stop treatment?
 Chair: Christina Duesing (Düsseldorf, DE)
 Discussants: Xavier Mariette (Paris, FR), Andrea Doria (Padua, IT), Ricard Cervera (Barcelona, ES), Zoe Karakikla Mitsakou (Lupus Europe, UK)
- 17.15 - 18.00 **Fishbowls V - VIII**
- V Chamber Music Room**
Glucocorticoids: Tapering to zero?
 Sponsored session – see page 77
- VI Studio 1**
What is the optimal management of fatigue?
 Chair: Daliya Pencheva (Sofia, BG)
 Discussants: Carlos Vasconcelos (Porto, PT), Marta Mosca (Pisa, IT), Laurent Arnaud (Strasbourg, FR), Ida Povilaite (Lupus Europe, LT)
- VII Green Room**
Pregnancy follow-up: How much is needed?
 Chair: Isabell Haase (Hamburg, DE)
 Discussants: Rebecca Fischer-Betz (Düsseldorf, DE), Véronique Le Guern (Paris, FR), Jane Salmon (New York, US), Dalila Tremarias (Lupus Europe, UK)
- VIII Angel Room**
How should the lupus community work together to get the best (but not the worst) out of Chat GPT?
 Chair: Christina Duesing (Düsseldorf, DE)
 Discussants: Anisur Rahman (London, UK), Antoine Enfrein (Brussels, BE), Ioannis Parodis (Solna, SE), Alain Cornet (Lupus Europe, BE)

18.00 End of day 2

19.30 Gala Dinner

- 07.45 **SLEuro General Assembly** **Chamber Music Room**
- 08.45 **Industry-Sponsored Symposium** (see page 79) **Concert Hall**

Parallel Sessions 17 & 18

- Session 17: Treatment of Nephritis II** **Concert Hall**
 Chairs: Ana Malvar (AR) & Eric Daugas (FR)

- 09.15 **I51** **Is lupus nephritis treatment different in Latin America?**
 Bernardo Pons-Estel, Rosario (AR)
- 09.35 **I52** **Discontinuation of maintenance therapy**
 Eric Daugas, Paris (FR)
- 09.55 **I53** **CKD therapy**
 Hans-Joachim Anders, München (DE)
- 10.15 **O43** **Three years is the minimal effective duration of sustained clinical remission associated with reduced risk of impaired kidney function and of damage accrual in lupus nephritis**
 Mariele Gatto, Giulia Frontini, Marta Calatroni, Claudio Cruciani, Luca Iaccarino, Francesco Reggiani, Renato Alberto Sinico, Gabriella Moroni, Andrea Doria (Italy)
- 10.25 **O44** **Long-term outcomes of chronic kidney disease patients with lupus nephritis: A nationwide cohort study**
 Charikleia Chrysostomou¹, Anne-Laure Faucon^{2,3}, Francesca Faustini¹, Iva Gunnarsson¹, Peter Barany⁴, Marie Evans⁴ (^{1,2,4}Sweden, ³France)

10.35 **Coffee Break (level 1 & 2) and Poster Viewing (level 3)**

07.45	SLEuro General Assembly	Chamber Music Room	11.00	Industry-Sponsored Symposium (see page 80)	Concert Hall
08.45	Industry-Sponsored Symposium (see page 79)	Concert Hall	11.30	Great Debate Chairs: Frédéric Houssiau (BE) & Nathalie Costedoat-Chalumeau (FR)	Concert Hall
Session 18: Pathophysiology				A minority of lupus patients (will) need a biologic Michelle Petri, Baltimore (US)	
Chairs: Elisabet Svengusson (SE) & Nan Shen (CN)				A majority of lupus patients (will) need a biologic David Isenberg, London (UK)	
		Chamber Music Room		Closing Ceremony	
09.15	I54	Navigating the complexities of lupus pathogenesis: novel players and targets for improved treatment Nan Shen, Shanghai (CN)		Light Lunch	
09.35	I55	Platelets in SLE Patrick Blanco, Bordeaux (FR)	12.30		
09.55	I56	When DNA loses nuclear control Martin Herrmann, Erlangen (DE)	12.45		
10.15	O45	Of mice and men: Using humanised HLA transgenic mouse models to explore the role of HLA in systemic lupus erythematosus <u>Thuvaraka Ware</u> , Carola Vinuesa (UK)			
10.25	O46	Distinct modular transcriptomic signatures associate with symptomatic fatigue and pain in ANA+ subjects both with and without clinically evolving SLE <u>Lucy Marie Carter</u> , Md Yuzaiful Md Yusof, Darren Plant, Julien Bauer, Stephanie Wenlock, Adewonuola Alase, Antonios Psarras, Zoe Wigston, Edward M. Vital (UK)			
10.35		Coffee Break (level 1 & 2) and Poster Viewing (level 3)			



Poster List



The presenters of the posters P1 through P80 are requested to be present at their posters for Q&A from 12.45 until 13.30 hrs on Wednesday 20 March.

Antiphospholipid syndrome

- P1 Intra-renal involvement in primary antiphospholipid antibodies syndrome: Data from two Italian centers**
Liala Moschetti, [Micaela Fredi](#), Massimo Radin, Mattia Zappa, Stefania Affatato, Dario Roccatello, Federico Alberici, Laura Andreoli, Franco Franceschini, Savino Sciascia, Angela Tincani (Italy)
- P2 Catastrophic antiphospholipid syndrome during COVID-19 pandemic**
[Diana Méndez-Nungaray](#), Haidee Torres-Avelar, Alejandro Ortiz-Hernández, Luis Jara-Quezada (Mexico)
- P3 Antiphospholipid syndrome with thrombosis of the superior vena cava, brachiocephalic, subclavian, external carotid, internal carotid veins, and right side of the sigmoid sinus of the brain in a 14-year-old patient: Case report**
Agnieszka Gazda, [Irina Naishtetik](#), Beata Kołodziejczyk, Piotr Gietka, Joanna Kulig, Paweł Łaguna (Poland)
- P4 Budd-Chiari syndrome as initial presentation of antiphospholipid syndrome: Case report**
[Haidee Torres-Avelar](#), Diana Méndez-Nungaray, Isabel Martínez-Núñez (Mexico)
- P5 Patients with obstetric antiphospholipid syndrome have constitutively higher complement activation compared to healthy controls**
[Margherita Zen](#), Marta Tonello, Maria Favaro, Filippo Vesentini, Teresa Del Ross, Ilenia Anna Gennaio, Antonella Calligaro, Federico Arru, Merra Noemi, Claudio Cruciani, Andrea Doria (Italy)

Biomarkers, cytokines, complement, autoantibodies

- P6 Increased interleukin-6 (IL-6) receptor shedding under interferon- α and IL-6 explains the relatively low C-reactive protein (CRP) levels in SLE patients**
Martyna Hempel, Erik Klapproth, Annika Krause, Babett Heschel, Nicolai Leuchten, Ali El-Amouche, Adelheid Korb-Pap, [Martin Aringer](#) (Germany)
- P7 Systemic lupus erythematosus: A study of metabolomic profile in Brazilian patients**
Vanessa Fausto, Jeferson Ursulino, Larissa Pinto, Jaciel Clementino, Patrícia Sampaio Leite, [Thiago Fragoso](#) (Brazil)
- P8 Novel endothelial progenitor cells populations as biomarkers of damage and remission in systemic lupus erythematosus**
Carlos Rafael-Vidal, Sara Martínez-Ramos, Beatriz Malvar-Fernández, [Irene Altabás-González](#), Coral Mouriño, Pablo Pazos-López, Arturo Fraga-Bau, José María Pego Reigosa, Samuel García (Spain)

- P9 Increase of IL10 and IFA2 are associated to clinical activity in systemic lupus erythematosus patients**
Elena Grau García, Iago Alcántara Álvarez, Inmaculada Chalmeta Verdejo, Hikmat Charia, Marta de la Rubia Navarro, Luis González Puig, Anderson Víctor Huaylla Quispe, José Ivorra Cortés, [Samuel Leal](#), Isabel Martínez Cordellat, Laura Mas Sánchez, Pablo Francisco Muñoz Martínez, Rosa Negueroles Albuixech, José Eloy Oller Rodríguez, Daniel Ramos Castro, Carmen Riesco Bárcena, Alba Torrat Novés, Ernesto Tovar Sugrañes, Elvira Vicens Bernabeu, Belén Villanueva Mañes, Inés Cánovas Olmos, Carmen Nájera Herranz, Guillen Sada Urmeneta, José Andrés Román Ivorra (Spain)
- P10 IL-16 expression in kidney biopsies from patients with SLE- and antiphospholipid syndrome- associated renal thrombotic microangiopathy and renal IgA vasculitis**
[Aliisa Häyry](#), Vilija Oke, Elisabet Svenungsson, Francesca Faustini, Iva Gunnarsson (Sweden)
- P11 TLR7 and TLR9 mediated interferon response in incomplete systemic lupus erythematosus**
Svenja Henning, Johanna Westra, Berber Doornbos - van der Meer, Barbara Horvath, Hendrika Bootsma, Karina de Leeuw (The Netherlands)
- P12 Sensitivity differences in ELISA versus ELiA for detecting anti-dsDNA antibodies: Awareness for the clinician**
[Anna Kohn](#), Maudí de Jong, Merlijn van den Berg, Arjan Kwakernaak, Ester van Leeuwen, Arianne Brandsma, Dieneke Schonenberg-Meinema (The Netherlands)
- P13 Acquired ficolin-3 deficiency in patients with systemic lupus erythematosus**
[Linnea Lindelöf](#)¹, Solbritt Rantapää-Dahlqvist², Christian Lundtoft³, Johanna K. Sandling³, Dag Leonard³, Ahmed Sayadi³, Lars Rönnblom³, Helena Enocsson⁴, Christopher Sjöwall⁴, Andreas Jönsen⁵, Anders A. Bengtsson⁵, Mun-Gwan Hong⁶, Lina-Marcela Diaz-Gallo⁷, Matteo Bianchi⁸, Sergey V. Kozyrev⁸, Kerstin Lindblad-Toh^{8,9}, the DISSECT Consortium, the ImmunoArray Consortium, Kristina Nilsson Ekdahl^{1,10}, Bo Nilsson¹, Iva Gunnarsson⁷, Elisabet Svenungsson⁷, Oskar Eriksson¹ (^{1-8:10}Sweden, ⁹USA)
- P14 High frequency of ITP related auto-antibodies in patients with active SLE**
Anders Bengtsson¹, John W. Semple^{2,3}, Leendert Porcelijn⁴, Rick Kapur⁵, [Petrus Linde](#)¹ (¹⁻³Sweden, ⁴⁻⁵The Netherlands)
- P15 Oxidative stress in incomplete systemic lupus erythematosus patients compared to systemic lupus erythematosus and healthy controls**
[Lu Liu](#), Svenja Henning, Karina de Leeuw, Berber Doornbos-van der Meer, Harry van Goor, Johanna Westra (The Netherlands)
- P16 Serum calprotectin levels in patients with systemic lupus erythematosus and association with disease activity - Single centre study**
[Daniela Marasović Krstulović](#), Karla Vrkić, Jasenka Oreb, Marin Petrić, Luka Milovac, Dijana Perković (Croatia)

- P17 Autophagy-based unconventional secretion of B cell activating factor (BAFF) by monocytes in Systemic Lupus Erythematosus (SLE)**
 Dimitra Nikoleri¹, Maria Semitekolou¹, Aikaterini Gkirtzimanaki², Spiros Georgakis³, Panagiotis Verginis², Prodromos Sidiropoulos^{1,2,4}, George Bertias^{1,2,4} (^{1,2,4}Greece, ³Switzerland)
- P18 Proteomic analysis of Cutaneous Lupus Erythematosus (CLE) dermal infiltrates and control skin reveals differentially upregulated and downregulated pathways**
 Timothy B. Niewold¹, Alexander Meves², Julia Lehman³, Surendra Dasari⁴, Karin Popovic-Silwerfeldt⁵, Cristine Charlesworth⁶, Benjamin Madden⁶, Elisabet Svenungsson^{7,8}, Vilija Oke^{8,9} (^{1,4,6}USA, ^{5,7-9}Sweden)
- P19 Regulation of monocyte intracellular metabolism in the inflammatory environment of Systemic Lupus Erythematosus (SLE)**
Konstantina Pambouka, Chrysoula Stathopoulou, Sofia Papanikolaou, Dimitra Nikoleri, Despoina Kosmara, Dimitris Konstantopoulos, Prodromos Sidiropoulos, Maria Semitekolou, George Bertias (Greece)
- P20 Interleukins as potential factors in assessing the disease activity in systemic lupus erythematosus**
Patricia Richter, Maria Alexandra Burlui, Cristina Andreea Adam, Ioana Bratoiu, Vasile Lucian Boiculescu, Elena Rezus (Romania)
- P21 Discovery of potential urinary biomarkers from Korean patients with systemic lupus erythematosus**
 Ji-Won Kim, Wook-Young Baek, Chang-Hee Suh (Korea)
- P22 Consistent benefits from belimumab irrespective of antiphospholipid autoantibody profile, yet not in the presence of lupus anticoagulant**
 Alexander Tsoi, Julius Lindblom, Nursen Cetrez, Ioannis Parodis (Sweden)
- P23 Presence of anti-Sm autoantibodies is associated with abatement of attainability of LLDAS and DORIS remission in systemic lupus erythematosus**
 Maria Helena Lourenço, Nursen Cetrez, Alexander Tsoi, Julius Lindblom, Dionysis Nikolopoulos, Ioannis Parodis (Sweden)
- P24 Differentiated monocytes express the pDC markers BDCA-2 and CD123**
 Antonios Psarras, Zoe Wigston, Ade Alase, Edward M. Vital (UK)
- P25 Leukocyte cell surface expression of urokinase plasminogen activator receptor (uPAR) in patients with systemic lupus erythematosus**
Astrid Welin, Lina Wirestam, Jesper Karlsson, Jonas Wetterö, Helena Enocsson, Christopher Sjöwall (Sweden)
- P26 In remitted SLE patients BAFF/BlyS serum levels measured at the time of immunosuppressant discontinuation are higher in patients with subsequent flares**
Margherita Zen, Claudio Cruciani, Filippo Vesentini, Federico Arru, Ilenia Anna Gennaio, Merra Noemi, Chiara Franco, Luca Iaccarino, Anna Ghirardello, Andrea Doria (Italy)

- P27 Role of IL-10 -secreting cells in the pathogenesis of Systemic Lupus Erythematosus (SLE)**
Claudia Iannone, Maria Gerosa, Chiara Vasco, Lorenza Maria Argolini, Nadia Pulvirenti, Giulia Carrea, Ilaria Suardi, Roberto Caporali, Jens Geginat (Italy)

Classification and subsets

- P28 Drug-induced lupus: Clinical and serological features in a tertiary hospital**
Samuel Leal, Iago Alcántara Álvarez, Inmaculada Chalmeta Verdejo, Hikmat Charia, Marta de la Rubia Navarro, Luis González Puig, Elena Grau García, Anderson Víctor Huaylla Quispe, José Ivorra Cortés, Isabel Martínez Cordellat, Laura Mas Sánchez, Pablo Francisco Muñoz Martínez, Rosa Negueroles Albuixech, José Eloy Oller Rodríguez, Daniel Ramos Castro, Carmen Riesco Bárcena, Alba Torrat Novés, Ernesto Tovar Sugrañes, Elvira Vicens Bernabeu, Belén Villanueva Mañes, Inés Cánovas Olmos, Carmen Nájera Herranz, José Andrés Román Ivorra (Spain)
- P29 Augmenting the potential of combined real-world connected clinical and claims data sources to characterize the heterogenous profiles of patients with lupus: A French case study (Lupus REAL)**
 Marc Jouve, Eymeric Lagonotte, Marion Valette, Barbara Lebas, Batourou Sano, Elodie Lehmann, Vincent Vuible (France)
- P30 Polyautoimmunity phenomenon in Systemic Lupus Erythematosus (SLE): Secondary Sjogren Syndrome (sSS)**
Cristiana Sieiro Santos, Clara Moriano Morales, Carolina Álvarez Castro, Elvira Diez Alvarez (Spain)
- P31 A novel disease endotype in SLE characterized by B cell hyperactivity, Sm/RNP reactivity and higher disease activity**
Hugo J. van Dooren¹, Yemil Atisha-Fregoso², Annemarie L. Dorjée¹, Tom W.J. Huizinga¹, Meggan Mackay², Cynthia Aranow², Rene E.M. Toes¹, Betty Diamond², Jolien Suurmond¹ (¹The Netherlands, ²USA)

Clinical manifestations

- P32 Knowledge of primary care professionals regarding systemic lupus erythematosus: The case of Tunisia**
Houssein Abida, Zeineb Meddeb, Cherifa Abdelkefi, Sana Toujani, Amira El Ouni, Saloua B'chir Hamzaoui, Thara Larbi, Kamel Bouslama (Tunisia)
- P33 Male lupus characteristics from multi ethnic cohort**
Hebatala M.M. Aldeyarbi, Susan George, Griffith Marchan, Ravindra Rajakariar, Andrea Cove-Smith, Angela Pakozdi, Malvina Cunningham, Myles Lewis, Benjamin Turner, Debasish Pyne (UK)

- P34 Lung involvement in patients with systemic lupus erythematosus: Multicenter study**
 Lorenza Maria Argolini, Isabella Scotti, Carolina Artusi, Maria Rosa Pellico, Giuseppe Alvise Ramirez, Luca Moroni, Enrica Bozzolo, Ludovica Cavallo, Chiara Bellocchi, Lorenza Beretta, Lorenzo Dagna, Roberto Caporali, Maria Gerosa (Italy)
- P35 Systemic lupus erythematosus with severe multiorgan involvement and tuberculosis in a young female patient: A case report**
 Dubravka Bosnic (Croatia)
- P36 Lupus myocarditis: The role of cardiac MRI and endomyocardial biopsy as diagnostic parameters**
 Riette du Toit, Sumanth Karamchand, Megan Rajah, Jacob Cilliers, Philip Herbst, Anton Doubell (South Africa)
- P37 Risk factors for loss functional capacity in systemic erythemathousus lupus: A cross sectional study**
 Tenildo Lopes, Larissa Pinto, Vanessa Fausto, [Thiago Fragoso](#) (Brazil)
- P38 Role of conventional magnetic resonance imaging in the evaluation of patients with neuropsychiatric involvement in Systemic Lupus Erythematosus (SLE)**
[Antonio Marangoni](#)¹, Carlo Garaffoni¹, Ettore Silvagni¹, Simone Appenzeller⁴, George Bertσίας², Antonis Fanouriakis³, Matteo Piga⁵, Marcello Govoni¹, Alessandra Bortoluzzi¹ (1⁵Italy, 2³Greece, 4Brazil)
- P39 Analysis of nailfold capillaroscopy findings and clinical features of patients with systemic lupus erythematosus and pulmonary arterial hypertension**
[Emiliano Marasco](#)¹, Christina Duesing², Stephanie Keymel³, Giovanni Zanframundo⁴, Veronica Codullo⁴, Oliver Sander², Gamal Chehab², Jutta Richter², Rebecca Fischer-Betz², Claudia Bracaglia⁵, Sezgin Sahin⁶, Konstantinos Triantafyllias⁷, Andreas Schwarting⁷, Lisa Keller⁸, Alain Meyer⁹, Matthieu Canuet¹⁰, Marianne Riou¹⁰, Ilaria Cavazzana¹¹, Micaela Fredi¹¹, Franco Franceschini¹¹, Ettore Silvagni¹², Alessandra Bortoluzzi¹², Carlo Alberto Scirè¹², Carlomaurizio Montecucco⁴, Lorenzo Cavagna⁴, Matthias Schneider² (1^{4-5,11-12}Italy, 2³⁻⁷⁻⁸Germany, 6^{Turkey}, 9¹⁰France)
- P40 Medial temporal lobe subregion volumes in systemic lupus erythematosus patients**
 Zahra M. Najeeb¹, Andreas Jönsen², Kristoffer Zervides^{2,3}, Petra C. Nilsson³, Anders Bengtsson², Tim Salomonsson¹, Gregory Kuchcinski^{4,5}, Pia C. Sundgren^{1,6,7}, Laura Wisse¹ (1³⁻⁶⁻⁷Sweden, 4⁵France)
- P41 Assessment of cognitive function in a randomized, placebo-controlled, interventional trial conducted in patients with moderate-to-severe systemic lupus erythematosus (SLE)**
 Evan D. Remington, Jelena Curcic, Kristin Hannesdottir, Alexandre Avrameas, Tirtha Sengupta, Carole Sips, Valeria De Luca, [Stephen J. Oliver](#) (Switzerland)

- P42 Management and clinical outcomes in 359 patients with SLE followed long-term in a specialist centre – Effect of sex, ethnicity and age at presentation**
 Nidhi Rege, Maria Pisiakova, David Isenberg, [Anisur Rahman](#) (UK)
- P43 Management and clinical outcomes in 359 patients with SLE followed long-term in a specialist centre – changes over time**
 Maria Pisiakova, Nidhi Rege, David Isenberg, [Anisur Rahman](#) (UK)
- P44 The presentation of systemic erythematosus lupus with Kikuchi-Fujimoto disease**
[Ervin Rapushi](#), Elsuarata Calliku, Edlira Petoshati, Majlinda Ikononi (Albania)
- P45 Specialists' comfort with cutaneous lupus erythematosus reveals potential gaps and a need for co-management strategies**
 Ryan Rex, [Sawyer May](#), Joseph F. Merola (USA)
- P46 Cutaneous and systemic lupus erythematosus in Nicaragua: A cross-sectional study**
[Jennifer Rodak](#), Adrian Loerbroks, Johana Blandón, Ralph Brinks (Germany)
- P47 Organ calcifications in patients with systemic lupus erythematosus**
 Tobias Schmidt, Amanda Hempel Zinglersen, Katrine Kjær Iversen, Louise Diederichsen, Andreas Fuchs, Søren Jacobsen (Denmark)
- P48 Differentiated anatomical distribution of cardiovascular calcifications in patients with Systemic Lupus Erythematosus (SLE) compared to healthy population controls (HC)**
[Tobias Schmidt](#), Amanda Hempel Zinglersen, Katrine Kjær Iversen, Andreas Fuchs, Søren Jacobsen (Denmark)
- P49 Prevalence of neutropenia and association with infections in systemic lupus erythematosus: A Swedish single-center experience over 14 years**
 Muna Saleh, Johanna Sjöwall, Marcus Bendtsen, [Christopher Sjöwall](#) (Sweden)
- P50 Hypertrophic pachymeningitis a revealing manifestation of systemic lupus erythematosus: A case report**
[Wafa Skouri](#), Haifa Tounsi, Yosr Abid, Mayssa Bouzidi, Jafer Ouni, Siwar Sbahi, Walid Zbiba, Khaled Bouzeidi, Raja Amri (Tunisia)
- P51 First case of lupus: Bishop Eraclius of Liège, Belgium**
[Donald Thomas](#), R. Hal Scofield (USA)
- P52 Hemiballism hemichorea as a debut of systemic lupus erythematosus – A case report**
[Haidee Torres Avelar](#), Diana Méndez Nungaray, Pedro Javier Villegas Medina (Mexico)
- P53 Multimorbidity in systemic lupus erythematosus**
 Marketa Dudkova, [Jakub Videman](#), Pavel Horak, Martina Skacelova, Adela Skoumalova (Czech Republic)

- P54 Screening for primary aldosteronism in hypertensive patients with systemic lupus erythematosus: Are we doing it enough?**
Matthew Wong, Alberta Y. Hoi, Joanna R. Kent, Eric F. Morand, Jun Yang, Fabien B. Vincent (Australia)

Damage and survival

- P55 Treatment patterns, corticosteroid use and associated comorbidities in systemic lupus erythematosus**
Tali Eviatar, Vered Rosenberg, Roni Yahalom-Golan, Idit Livnat, Gabriel Chodick, Daphna Paran (Israel)

- P56 Coronary artery calcification in Danish SLE patients without known cardiovascular disease: Comparison with the general population, myositis and diabetes patients**
Susan Due Kay, Axel C.P. Diederichsen, Louise P. Diederichsen, Mikael Kjær Poulsen, Jess Lambrechtsen, Flemming Hald Steffensen, Niels Peter Sand, Hans Mickley, Jes Lindholt, Søren Jacobsen, Jacob Hjelmborg, Anne Voss (Denmark)

- P57 Stress perfusion Cardiac Magnetic Resonance imaging (CMR) changed medical management in SLE patients with chest pain**
Isak Samuelsson^{1,2}, Simon Thalén^{3,4}, Giorgia Grosso^{2,5}, Magnus Lundin⁶, Peder Sörensson^{2,3}, Henrik Engblom^{3,4}, Martin Ugander, M.^{3,4,7,8}, Elisabet Svenungsson^{2,5} (¹⁻⁶Sweden, ⁷⁻⁸Australia)

- P58 Menopausal age and the effect of menopause on disease activity in SLE**
Esin Beste Yilmaz, Agneta Zickert, Iva Gunnarsson, Elisabet Svenungsson, Aleksandra Antovic (Sweden)

- P59 Systemic disease activity as a driver of neuronal affliction in SLE: A longitudinal study**
Kristoffer A. Zervides, Elsa Grenmyr, Shorena Janelidze, Birgitta Gullstrand, Jessika Nystedt, Petra C. Nilsson, Pia C. Sundgren, Oskar Hansson, Anders A. Bengtsson, Andreas Jönsen (Sweden)

Flares and remission / Disease activity

- P60 Performance of SLE-DAS to assess subcutaneous belimumab efficacy in a cohort of systemic lupus erythematosus patients**
Fulvia Ceccarelli, Licia Picciariello, Francesco Natalucci, Valeria Moretti, Francesca Romana Spinelli, Cristiano Alessandri, Fabrizio Conti (Italy)

- P61 Harnessing machine learning to predict neuropsychiatric events in systemic lupus erythematosus**
Nursen Cetrez, Julius Lindblom, Raffaele Da Mutten, Dionysis Nikolopoulos, Ioannis Parodis (Sweden)

- P62 Machine learning approaches for prediction of renal flares in systemic lupus erythematosus: Knowledge-driven models outperformed data-driven models**
Nursen Cetrez, Julius Lindblom, Raffaele Da Mutten, Dionysis Nikolopoulos, Ioannis Parodis (Sweden)

- P63 Time is important: Implications of disease duration and age for systemic erythematosus lupus neuroimaging**
Luana Barros de Lima, Lucas Bomfim, Laís Pedroza, Jorge Arthur Coelho, Thiago Fragoso (Brazil)

- P64 Evaluation of changes in SLE patients' phenotype at disease onset, and assessment of disease activity, damage and therapy at diagnosis and during follow up in the last forty years: Preliminary data of a single center experience**
Micaela Fredi, Silvia Ebe Lucia Della Pina, Claudia Barison, Chiara Orlandi, Marzia Tedeschi, Chiara Mai, Cecilia Nalli, Franco Franceschini (Italy)

- P65 Cluster-based propensity score analysis of glucocorticoid usage and lupus remission: A pilot study**
Halbert Hernández-Negrin^{1,2,3}, Diana Paredes-Ruiz³, Maria Herrero-Galvan⁴, Victor Moreno-Torres^{3,5,6}, Ioana Ruiz-Arruza^{3,4}, Cedric Leonard⁷, Pierre Duffau⁷, Christophe Richez⁷, Patrick Blanco⁷, Estibaliz Lazaro⁷, Guillermo Ruiz-Iratorza^{3,4} (¹⁻⁶Spain, ⁷France)

- P66 Cutaneous vasculitis in patients with active versus inactive systemic lupus erythematosus: A case series**
Catherine Grace Hobayan, Abraham Korman, Judith Lin (USA)

- P67 The SLE-DAS enables easy identification of SLE patients with severe disease activity and worse health-related quality of life: Derivation and validation in post-hoc study of anifrolumab phase 2 and 3 clinical trials**
Diogo Jesus^{1,2}, Carla Henriques^{3,4}, Ana Matos^{3,5}, Andrea Doria⁶, Luís Sousa Inês^{2,7} (^{1-5,7}Portugal, ⁶Italy)

- P68 Comparative analysis of efficiencies of immunosuppressive drugs in SLE with different clinical presentation and their molecular stratification: A prospective study from India**
Abhibroto Karmakar, Uma Kumar, Smita Prabhu, Vinod Ravindran, Shankar Prasad, Varashree B.S., Subhradip Karmakar, Mukhyaprana M. Prabhu (India)

- P69 Methyl-prednisolone pulses and prolonged remission in systemic lupus erythematosus: A propensity score analysis of the longitudinal Lupus-Cruces-Bordeaux inception cohort**
Diana Paredes¹, María Herrero-Galvan², Victor Moreno-Torres^{1,3}, Halbert Hernandez-Negrin^{1,4,5}, Ioana Ruiz-Arruza^{1,2}, Cedric Leonard⁵, Pierre Duffau⁶, Christophe Richez⁶, Patrick Blanco⁶, Estibaliz Lazaro⁶, Guillermo Ruiz-Iratorza^{1,2} (¹⁻⁵Spain, ⁶France)

- P70 Exposure to DORIS ≥50% of time and to LLDAS ≥60% of observation time exhibit the best combination of feasibility and protection against adverse outcomes in moderate-to-severe SLE**
Sofia Pitsigavdaki¹, Myrto Nikoloudaki¹, Panagiotis Garantzotis^{2,3}, Ettore Silvagni³, Argyro Repa¹, Antonio Marangoni³, Irini Flouri¹, Nestor Avgoustidis¹, Konstantinos Parperis⁴, Marcello Govoni³, Prodromos Sidiropoulos^{1,6}, Dimitrios Boumpas^{3,7}, Alessandra Bortoluzzi³, George Bertias^{1,6} (^{1,3,6-7}Greece, ⁴Italy, ⁵Cyprus)
- P71 Treatment patterns, healthcare resource utilization and related costs of patients with discoid lupus erythematosus (DLE) or Subacute Cutaneous Lupus Erythematosus (SCLE) in the United States: A cohort study in the Merative™ MarketScan® database**
Caroline Foch¹, Sabrina de Souza¹, Ying Sun², Xiaoxue Chen³, Sanjeev Roy⁴, Dominika Weinelt⁵, Jeffrey M. Muir⁶, Benjamin F. Chong⁷ (^{1,2,5}Germany, ^{3,7}USA, ⁴Switzerland, ⁶Canada)
- P72 Glucocorticoid discontinuation after remission achievement in not associated with an increased risk of flares**
Filippo Vesentini, Federico Arru, Rosanna Somma, Noemi Merra, Cristina Cadore, Ilenia Gennaio, Claudio Cruciani, Luca Iaccarino, Margherita Zen, Andrea Doria (Italy); Presenter: Zahra Rahmé
- P73 Predictors of flares after glucocorticoid discontinuation in remitted patients with SLE**
Filippo Vesentini, Federico Arru, Rosanna Somma, Noemi Merra, Cristina Cadore, Ilenia Gennaio, Claudio Cruciani, Luca Iaccarino, Margherita Zen, Andrea Doria (Italy)
- P74 Late-onset monogenic lupus: A case-based review**
Esra Firat Senturk, Bilal Berke Ayvaz, Sinem Firtina, Serdal Ugurlu (Turkey)
- P75 Molecular exploration of Systemic Lupus Erythematosus (SLE) sexual dimorphism uncovers a crucial role of SMC1A in transcriptional regulation of inflammation**
Despoina Kosmara, Sofia Papanikolaou, Chrysoula Stathopoulou, Giannis Vatsellas, Aggelos Banos, Prodromos Sidiropoulos, Dimitrios Boumpas, Dimitris Konstantopoulos, George Bertias (Greece)
- P76 Established risk alleles at HLA-A, -DPB1, -DQB1 and -DRB1 for systemic lupus erythematosus associate with distinct clinical manifestations**
Henrik Christian Bidstrup Leffers^{1,2,3}, Ingileif Jonsdottir^{4,5}, Saedis Saevarsdottir^{4,5}, Ole Birger Pedersen^{6,16}, DBDS genomic consortium, Anne Trolborg⁷, Anne Voss⁸, Salome Kristensen^{2,9}, Jesper Lindhardsen¹, Prabhat Kumar¹¹, Asta Linauskas^{10,11}, Lars Juul¹², Niels Steen Krogh^{2,13}, Bent Deleuran⁷, Lene Dreyer^{9,10}, Michael Schwinn³, Lise Wegner Thøner¹⁴, Lotte Hindhede¹⁵, Christian Erikstrup^{15,16}, Sisse Rye Ostrowski^{14,17}, Søren Brunak¹⁸, Kari Stefansson^{4,5}, Søren Jacobsen^{1,17} (^{1,3,6-18}Denmark, ⁴⁻⁵Iceland)
- P77 Identification of a cluster of SLE risk loci associated with levels of multiple blood biomarkers in the general population – Implication for SLE sub-phenotypes**
Nina Oparina¹, Sarah Reid¹, Ahmed Sayadi¹, Maija-Leena Eloranta¹, Martina Frodlund², Karoline Lerang³, Andreas Jönsen⁴, Solbritt Rantapää-Dahlqvist⁵, Anders A. Bengtsson⁴, Anna Rudin⁶, Øyvind Molberg³, Christopher Sjöwall², Lars Rönnblom¹, Dag Leonard¹ (^{1,2,4-6}Sweden, ³Norway)

- P78 Thrombotic Thrombocytopenic Purpura (TTP) in an SLE patient successfully treated with plasma exchange, caplacizumab and rituximab**
Ivan Padjen, Marija Bakula, Branimir Anic (Croatia)
- Lupus in minorities**
- P79 Clinical features and prevalence of late and very late onset systemic lupus erythematosus**
Ilenia Anna Gennaio¹, Margherita Zen¹, Filippo Vesentini¹, Federico Arru¹, Zahra Rahmé¹, Luca Iaccarino¹, Mariele Gatto², Maddalena Larosa¹, Enrico Fuzzi³, Andrea Doria¹ (^{1,2}Italy, ³Sweden)
- P80 Epidemiology of lupus disease in Mayotte from 2015 to 2023**
Karim Abdelmoumen, Sarah Permal (France)

The presenters of the posters P81 through P165 and LBP1 through LBP6 are requested to be present at their posters for Q&A from 12.45 until 13.30 hrs on Thursday 21 March.

Lupus nephritis

- P81 Light chain deposition in the kidneys of patients with lupus nephritis**
 Tamara Knežević, Vanja Ivković, Ivan Padjen, Mario Laganović, Zrinka Biloglav, Stela Bulimbašić, Marijana Ćorić, Branimir Anić (Croatia)
- P82 Health literacy status and its correlates among patients with lupus nephritis**
 Cameron Bonthron, Luxme Nadarajah, Angela Pakozdi, Debasish Pyne, Andrea Cove-Smith, Ravindra Rajakariar (UK)
- P83 Long-term prognosis of lupus nephritis: Comparison between pediatric, adult, and advanced age onset**
 Marta Calatroni, Federico Doti, Federica Bello, Giovanni De Vivo, Antonio Mastrangelo, Francesco Reggiani, Maria Gerosa, Lorenza Maria Argolini, Laura Locatelli, Rossella Valentino, Gabriella Moroni (Italy)
- P84 Regular monitoring of anti-C1q antibodies can be of help to predict Lupus Nephritis (LN) exacerbations**
Marta Calatroni, Emanuele Conte, Federica Bello, Matteo Stella, Francesco Reggiani, Gabriella Moroni (Italy)
- P85 Predictors of LLDAS and remission in a single-center cohort of patients with lupus nephritis: A retrospective analysis**
Francesca Cirilli, Carlo Garaffoni, Giorgio Galoppini, Ettore Silvagni, Marcello Govoni, Alessandra Bortoluzzi (Italy)
- P86 Rituximab therapy in lupus nephritis resistant to conventional therapy – A single center experience (case series)**
Esra Firat Senturk, Hande Ogun, Ibrahim Durucan, Berna Yurttas, Serdal Ugurlu (Turkey)
- P87 Comparison of a voclosporin-based, triple immunotherapy regimen to high-dose glucocorticoid-based immunosuppressive therapy: A propensity analysis of the AURA-LV plus AURORA 1 studies and ALMS**
 Maria Dall'Era^{1,5}, Kenneth Kalunian², Anca Askanase³, Neil Solomons⁴, Matt Truman⁵, Lucy Hodge⁵, Ernie Yap⁵ (^{1-2,5}USA, ³⁻⁴Canada)
- P88 Baseline factors associated with subsequent development of incident nephritis in patients with systemic lupus erythematosus: a retrospective cohort study**
Spyridon Katechis, Dionysis Nikolopoulos, Sofia Flouda, Katerina Chavatzia, Noemí Kapsala, Pelagia Katsimbri, Dimitrios T. Boumpas, Antonis Fanouriakis (Greece)
- P89 IL-28 as potential therapeutic target for LN**
 Myriam Meineck, Andreas Kommer, Sebastian Linsel, Sabrina Saurin, Tamara Möckel, Andrea Pautz, Andreas Schwarting, Julia Weinmann-Menke (Germany)

- P90 Use of belimumab in patients with lupus nephritis refractory to standard treatment**
Luxme Nadarajah, Cameron Bonthron, Angela Pakozdi, Debasish Pyne, Andrea Cove-Smith, Ravindra Rajakariar (UK)
- P91 Effective treatment of lupus nephritis and vasculitic fibrinoid necrotic ulcer with belimumab as add-on therapy**
Anuoluwapo R. Oke, Khin Yein, Azeem Ahmed (UK)
- P92 Quantifying the unmet need in lupus nephritis: EULAR/ERA- EDTA treatment targets, flares, and treatment modifications in the first year in a multicenter observational study**
Maria Pappa, Maria Kosmetatou, Antigone Pieta, Flora Chouzouri, Evangelia Argyriou, Christina Tsalapaki, Aglaia Chalkia, Theodoros Dimitroulas, Mirto Cheila, Georgios Demirtzoglou, Charalampos Papagoras, Andreas Goules, Christina Katsiari, Dimitrios Petras, Dimitrios Vassilopoulos, Prodromos Sidiropoulos, Kyriaki Boki, Petros P. Sfrikakis, Paraskevi V. Voulgari, George K. Bertias, Dimitrios T. Boumpas, Maria Tektonidou, Antonis Fanouriakis (Greece)
- P93 Investigation of clinical and laboratory characteristics and survival of SLE patients with and without lupus nephritis**
Bianka Perge, Bernadett Bóí, Eszter Gáspár-Kiss, Gábor Papp, Tünde Tarr (Hungary)
- P94 Long-term renal outcome in childhood-onset lupus nephritis**
Francesco Peyronel, Ludovica Odone, Marta Calatroni, Chiara Pala, Carmela Errichiello, Federico Doti, Federica Bello, Marco Delsante, Emanuele Conte, Giacomo Emmi, Giovanni Maria Rossi, Gabriella Moroni, Augusto Vaglio (Italy)
- P95 First two US patients with Lupus Nephritis (LN) treated with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy: Preliminary results from the KYSA-1 phase 1, multicenter study of KYV-101**
 Amber Podoll, Richard Furie, Francis Kim, Justin Chou, Ranjita Sengupta, Ruthee Bayer, Jonathan Gutman, James Chung (USA)
- P96 Prognostic factors for chronic kidney disease in patients with class V lupus nephritis in 4 reference centers in Mexico**
Ivette Ruiz-Leija, David Herrera-Van Oostdam, Jaime Borjas, Enrique Faugier, Sandra Rodríguez-Aguayo, Tayde Gracia-Aréchiga, Miguel Saavedra-Salinas, Fedra Irazoque, Lilia Andrade, Carlos Abud-Mendoza, Grupo de Estudio Potosino de Nefritis Lúpica (LUNPOS) (Mexico)
- P97 LNMap: A curated computational resource of molecular pathways in lupus nephritis**
 George Sentis¹, Chrysa Rapti¹, Maria Grigoriou^{1,2}, Eirini Maria Stergioti¹, Eleftherios Chavatzas¹, Panagiotis Garantziotis^{3,4}, Aggelos Banos¹, Marek Ostaszewski^{5,6}, Dimitrios T. Boumpas^{1,2}, Anastasia Filia¹ (¹⁻³Greece, ⁴Germany, ⁵⁻⁶Luxembourg)
- P98 Bone morphogenetic protein-7 as treatment in lupus nephritis: Getting from bench to bedside**
Carine Smith, Riette du Toit, Tracey Ollewagen (South Africa)

P99 Histological renal features and cytokines assessment as possible biomarkers in patients with systemic lupus erythematosus and lupus nephritis

Valentina Varriano, Clara Di Mario, Annamaria Paglionico, Luca Petricca, Maria Rita Gigante, Barbara Tolusso, Elisa Gremese (Italy)

New lupus drug /targeted therapies

P100 Efficacy of anifrolumab in multi-refractory skin manifestations of systemic lupus erythematosus: Case series

Sofia Flouda, Evgenia Emmanouilidou, Tasos Karamanakos, George Bertias, Dimitrios Boumpas, Antonios Fanouriakis (Greece)

P101 Anti-CD19 CAR-T cell therapy for refractory childhood-onset systemic lupus erythematosus

Emiliano Marasco, Claudia Bracaglia, Pietro Merli, Patricia Moran Alvarez, Rebecca Nicolai, Mattia Algeri, Maria Giuseppina Cefalo, Marco Becilli, Fabrizio De Benedetti, Franco Locatelli (Italy)

P102 Safety evaluation from an ongoing randomized, double-blind, multiple-ascending dose phase Ib study of enpatoran versus placebo in patients with active systemic or cutaneous lupus erythematosus (SLE/CLE)

Joerg Wenzel¹, Nadezda Abramova², Dominika Weinelt², Deborah Denis³, Sanjeev Roy⁴, Torsten Witte⁵ (^{1-2,4-5}Germany, ³USA)

P103 14-Deoxy-14-methyloxacyclododecindione: A new therapeutic approach of SLE?

Sabrina Saurin, Myriam Meineck, Till Opatz, Gerhard Erkel, Andrea Pautz, Julia Weinmann-Menke (Germany)

P104 Upregulation of both APRIL and BAFF in systemic lupus erythematosus suggests non-redundant roles, further revealed by potent dual inhibition with povetacept (TACI vTD-Fc; ALPN-303)

Katherine E. Lewis, Zahra Maria, Elizabeth Repash, Tiffany C. Blair, Amanda Enstrom, Lawrence S. Evans, Armand Bankhead III, Ismail Simsek, Stanford L. Peng, Stacey R. Dillon (USA)

P105 NEX-T CD19 chimeric antigen receptor (CAR) T-cell therapy CC-97540 (BMS-986353): Preclinical and translational evidence of deep B-cell depletion suitable for study in severe refractory autoimmune diseases

Georg Schett¹, Tatyana Feldman², Jeremy Abramson³, Boyu Hu⁴, Fabien Müller¹, Ashley Koegele⁵, Jerill Thorpe⁶, Ruth Salmon⁷, Fan Wu⁸, Divya Varun⁹, Alison Maier⁷, David Kugler^{7,10}, Matthew Westoby^{7,11}, Nikolay Delev¹², Amitkumar Mehta¹³ (¹Germany, ²⁻¹³USA)

Other

P106 Barriers and potential solutions to health disparities in patients with systemic lupus erythematosus: Insights from a focus group study

Donna Finale, Janine Gaiha-Rohrbach, Mina Nejati, George Stojan (USA); Presenter: Agnes Koncz

P107 Systemic Lupus Erythematosus (SLE) and subclinical musculoskeletal involvement: A role for osteoarticular ultrasound?

Andrea Amati, Claudia Iannone, Lorenza Argolini, Ilaria Magi, Raffaele Di Taranto, Carolina Artusi, Orazio De Lucia, Maria Gerosa, Roberto Caporali (Italy)

Outcome measures

P108 A 6-year prospective study on work participation and associated factors in Dutch patients with Systemic Lupus Erythematosus (SLE)

Birgit Blomjous, Marieke M. ter Wee, Michel Tsang-A-Sjoe, Cecile Boot, Alexandre Voskuy, Irene Bultink (The Netherlands)

P109 Utility of skin biopsy in patients with systemic lupus erythematosus

Catherine Grace Hobayan, Abraham Korman, Judith Lin (USA)

P110 Impact of neuropsychiatric involvement on health-related quality of life in patients with systemic lupus erythematosus

Dionysis Nikolopoulos, Nursen Cetrez, Julius Lindblom, Ioannis Parodis (Sweden)

P111 ASSESSLE, a new disease activity score for the assessment of systemic lupus erythematosus

Daphna Paran, Monique Ben-Am, Liran Mendel, Ari Polachek, Victoria Furer, Ofir Elalouf, Jonathan Wollman, Shaye Kivity, Nancy Agmon-Levin (Israel)

P112 Association of lupus low disease activity with health-related quality of life

Daliya Pencheva, Simeon Monov (Bulgaria)

P113 Complications after kidney biopsy in patients with lupus nephritis: Single center analysis and systematic literature review

Jan-Gerd Rademacher, Peter Korsten (Germany)

P114 Steroid-free remission in systemic lupus erythematosus - Is it an achievable goal and is it sustained over time? A real-life experience from a monocentric cohort

Dina Zucchi, Chiara Cardelli, Francesca Trentin, Viola Signorini, Chiara Stagnaro, Linda Carli, Francesco Ferro, Elena Elefante, Davide Schilirò, Michele Maffi, Giancarlo Cascarano, Luca Gualtieri, Anastasiya Valevich, Chiara Tani, Marta Mosca (Italy)

Pathophysiology

- P115 Belimumab treatment rapidly restores B cell homeostasis and reduces atypical T-bet⁺ B cell expansion in patients with systemic lupus erythematosus**
Fulvia Ceccarelli, Francesca La Gualana, Gabriella Cusa, Licia Picciariello, Giulio Olivieri, Begi Petriti, Francesco Natalucci, Maddalena Sciannamea, Marcella Visentini, Fabrizio Conti (Italy)
- P116 Cell surface glycosylation patterns reveal distinct circulating immune cell subsets with potential disease specificity in patients with active SLE**
László Kovács, Enikő Szabó, Gergely Bodor, Gábor J. Szebeni (Hungary)
- P117 Exploring mechanisms behind thrombosis in systemic lupus erythematosus**
Mads L. Larsen^{1,2}, Laura Nørgaard¹, Petrus Linge³, Julie B. Larsen^{4,5}, Henrik Z. Langkilde^{6,7}, Ellen M. Hauge^{2,5}, Steffen Thiel¹, Anne Voss^{6,7}, Anders Bengtsson³, Anne Trolborg^{1,2,5} (1-2:4-7Denmark, 3Sweden)
- P118 Increased atherothrombotic risk in SLE patients: The role of oxidative stress in fibrinogen structural and functional modifications**
Irene Mattioli, Alessandra Bettiol, Federica Bello, Amanda Mannucci, Flavia Rita Argento, Eleonora Fini, Maria Nicastro, Elena Silvestri, Niccolò Taddei, Augusto Vaglio, Domenico Prisco, Matteo Becatti, Claudia Fiorillo, Giacomo Emmi (Italy)
- P119 T-bet⁺ B cells can serve as prognostic and therapeutic tools for human systemic lupus erythematosus**
Athanasios Sachinidis, Maria Trachana, Anna Taparkou, Sofoklis Keisaridis, George Gavriilidis, Panayotis Verginis, Christina Adamichou, Dimitrios Boumpas, Alexandros Garyfallos (Greece)
- P120 Unveiling CD4⁺ metabolic dysregulation in systemic lupus erythematosus: Implications for targeting mitochondrial dysfunction**
Chris Wincup, Meredyth Wilkinson, Anna Radziszewska, George Robinson, Anisur Rahman (UK)

Patient's views and reported outcomes

- P121 Online support group for lupus patients: The Tunisian experience**
Housseem Abida, Zeineb Meddeb, Cherifa Abdelkefi, Sana Toujani, Amira El Ouni, Saloua B'chir Hamzaoui, Thara Larbi, Kamel Bouslama (Tunisia)
- P122 Skin disease burden in systemic lupus erythematosus: Data from a monocentric cohort**
Chiara Cardelli, Elena Elefante, Viola Signorini, Dina Zucchi, Francesca Trentin, Giancarlo Cascarano, Luca Gualtieri, Anastasiya Valevich, Michele Maffi, Davide Schilirò, Francesco Ferro, Linda Carli, Chiara Stagnaro, Chiara Tani, Marta Mosca (Italy)

- P123 Increased SLE burden in patients of lower economic status**
Alain Cornet, Jeanette Andersen, Zoe Karakikla (Belgium)
- P124 High throughput multiplex immunoassays stratify patients according to symptom burden across the Lupus-Sjögren's spectrum**
Sarah Dyball, Rudresh Shukla, Anastasia-Vasiliki Madenidou, Mia Rodziewicz, Maya Buch, Ben Parker, Ian N. Bruce (UK)
- P125 Patient's perception of the effectiveness and safety of corticosteroids in systemic lupus erythematosus**
Catarina Favas, Frederico Batista, Carolina Carvalho, Carolina Saca, Ana Sara Monteiro, Marisa Neves³, João Serôdio, José Delgado Alves (Portugal)
- P126 Association between health-related quality of life and physical activity in systemic lupus erythematosus patients from two centres in Portugal**
Koen F. de Koning¹, Daniel G. Oliveira^{2,3,4}, Natália Oliveira², Elva B. Andrade⁴, Paulo P. Costa³, Carlos Vasconcelos^{3,5} (1The Netherlands, 2-5Portugal)
- P127 The SLE-DAS enables easy identification of SLE patients with moderate-to-severe disease activity and worse HR-QoL in the screening for SLE clinical trials: A post-hoc study in the phase 2 and 3 anifrolumab trials**
Diogo Jesus^{1,2}, Ana Matos^{3,4}, Carla Henriques^{3,5}, Andrea Doria⁶, Luís Sousa Inês^{2,7} (1-5:7Portugal, 6Italy)
- P128 Amplifying the lupus patient voice: Insights into the diagnostic journey and informational needs**
Sawyer May, Maxine Yarnall, Ryan Rex (USA)
- P129 Does the perspective of SLE patients match the expert opinion and definitions of remission and low disease activity state? Prospective analysis of 500 patients from a Spanish multicenter cohort**
Coral Mourino Rodriguez^{1,2}, Jose Maria Pego Reigosa^{1,2}, Inigo Rua Figueroa³, Francisco Rubino³, Inigo Hernandez Rodriguez¹, Raul Menor Almagro⁴, Esther Uriarte Isacelaya⁵, Eva Tomero Muriel⁶, Tarek Salman Montes⁷, Irene Carrion Barbera⁷, Maria Galindo⁸, Esther Rodriguez Almaraz⁸, Norman Jimenez², Luis Ines⁹, Irene Altabas Gonzalez^{1,2} (1-8Spain, 9Portugal)
- P130 Patients' thoughts of triggers for lupus onset and flares**
Susanne Pettersson, Iva Gunnarsson, Elisabet Svenungsson (Sweden)
- P131 Development and usability test of a webapp "viver com lupus" to promote adjustment to systemic lupus erythematosus**
Sofia Silva-Ribeiro¹, Cristina A. Godinho², Marta M. Marques³, Deborah Antcliff⁴, Sónia F. Bernardes^{1(1-3Portugal, 4UK)}

P132 Exploring the impact of comorbidity, multimorbidity, and mental health conditions on health related outcomes in systemic lupus erythematosus: A global study
Gagandeep Sukhija¹, Eman Elfar¹, Amelia Holloway¹, Sook Yan Lee¹, Elena Nikiphorou^{1,2}, Ioannis Parodis^{3,4}, Naveen R⁵, Jessica Day^{6,7,8}, Mrudula Joshi⁹, Sreoshi Saha¹⁰, Syahrul Sazliyana Shaharir¹¹, Wanruchada Katchamart¹², Phonpen Akawatcharangura Goo¹³, Lisa S Traboco¹⁴, Yi Ming Chen^{15,16}, Parikshit Sen¹⁷, James B. Lilleker^{18,19}, Arvind Nune²⁰, John D Pauling^{21,22}, Ai Lyn Tan^{23,24}, Nelly Ziade^{25,26}, Marcin Milchert²⁷, Abraham Edgar Gracia-Ramos²⁸, Carlo Vinicio Caballero-Urbe²⁹, COVAD Study Group Vikas Agarwal³⁰, Rohit Aggarwal³¹, Latika Gupta^{32,33}, Chris Wincup^{1,2 (1-2,18-24,32-33)UK, 3-4Sweden, 5,9,17,30India, 6-8Australia, 10Bangladesh, 11Kuala Lumpur, 12-13Thailand, 14Philippines, 15-16Taiwan, 25-26Lebanon, 27Poland, 28Mexico, 29Colombia, 31USA)}

P133 Anifrolumab treatment improves quality of life and decreases corticosteroid use in patients with SLE
Anne Troldborg^{1,2}, Lauren Remkus³, Daniel Eek⁴, Bent Deleuran^{1,2 (1-2Denmark, 3Sweden)}

P134 Factors associated with discordance between patient and physician perception of disease activity among patients with systemic lupus erythematosus: An international collaborative study
 Shounak Ghosh¹, Rajagopal Sankara Narayanan², Katie Bechman³, Ioannis Parodis⁴, Esha Kadam⁵, Wanruchada Katchamart⁶, Phonpen Akarawatcharangura Goo⁷, Abraham Edgar Gracia-Ramos⁸, Parikshit Sen⁹, Elena Nikiphorou³, Sreoshi Saha¹⁰, Ai Lyn Tan¹¹, Tsvetelina Velikova¹², Marcin Milchert¹³, Johannes Knitza¹⁴, Carlo Caballero¹⁵, Dey Dzifa¹⁶, Hector Chinoy¹⁷, COVAD Study Group¹⁸, Rohit Aggarwal¹⁹, Vikas Agarwal²⁰, Latika Gupta²¹, Chris Wincup^{2,2 (1-2,5,9,17,20)India, 3,11,21,22UK, 4Sweden, 6-7Thailand, 8Mexico, 10Bangladesh, 12Bulgaria, 13Poland, 14Germany, 15Colombia; 16Ghana, 19USA)}

Pregnancy, fertility, and neonatal care

P135 Altered hemostatic balance towards procoagulant state in pregnant women with systemic lupus erythematosus
 Daniele Lini¹, Iva Gunnarsson², Nida Soutari³, Sanja Lalic-Cosic⁴, Andrea M.C. Nicholas², Roza Chaireti^{5,6}, Katarina Bremme⁷, Franco Franceschini¹, Elisabet Svenungsson², Laura Andreoli¹, Aleksandra Antovic^{2 (Italy, 2-3,5-7Sweden, 4Serbia)}

P136 Comparison of obstetric outcomes in two consecutive pregnancies in women with renal and non-renal systemic lupus erythematosus – A retrospective single-centre cohort study
Aleksandra Antovic, Roza Charieti, Elin Jacke, Katarina Bremme, Iva Gunnarsson (Sweden)

P137 Concentrations of subcutaneously administered belimumab in human breast milk in a woman with systemic lupus erythematosus: A case report
Birgit Blomjous, Marjon de Boer, Mirjam van Weissenbruch, Koen Laan, Theo Rispens, Alexandre Voskuyl, Irene Bultink (The Netherlands)

P138 Pregnancy outcomes in SLE patients treated with belimumab: The Italian experience
Francesca Crisafulli, Maria Chiara Gerardi, Maria Letizia Urban, Margherita Zen, Melissa Padovan, Valentina Canti, Emanuela Praino, Maria Gerosa, Cecilia Nalli, Francesca Ruffilli, Francesca Saccon, Micaela Fredi, Giacomo Emmi, Luca Iaccarino, Andrea Doria, Leonardo Santo, Franco Franceschini, Laura Andreoli, Angela Tincani (Italy)

P139 The FaMaLE study: Investigating failing maternal-fetal tolerance in pregnant women with SLE
Wendy Dankers, A. Parra Sanchez, K. Veeneman, A.M. O'Byrne, S.A. Germe, M.F.H.M. van Gaal, J.F. Ruitenbeek, M. de Boer, L.G.M. van Baarsen, I.E.M. Bultink (The Netherlands)

P140 Pregnancy and systemic lupus erythematosus: Experience in a pregnancy clinic
Elena Heras-Recuerdo, Antía García-Fernández, Fernando Rengifo-García, Teresa Blázquez-Sánchez, Raquel Senosiain-Echarte, Miguel Álvaro-Navidad, Miguel Ángel González-Gay, Juan Antonio Martínez-López (Spain)

P141 Effect of remission, clinical remission with active serology, and glucocorticoid dosage on the pregnancy outcome of pregnant patients with systemic lupus erythematosus
Takehiro Nakai¹, Nanase Honda², Eri Soga³, Sho Fukui^{1,4,5}, Ayako Kitada^{1,6}, Naoto Yokogawa², Masato Okada^{1 (1-4,6Japan, 5USA)}

P142 A retrospective analysis of the safety of tacrolimus use and its optimal cut-off concentration during pregnancy in women with systemic lupus erythematosus: Study from two Japanese tertiary referral centers
Takehiro Nakai¹, Nanase Honda², Eri Soga³, Sho Fukui^{1,4,5}, Ayako Kitada^{1,6}, Naoto Yokogawa², Masato Okada^{1 (1-4,6Japan, 5USA)}

P143 Efficacy of consultation before and during pregnancy on therapeutic adherence surveyed in a single-center cohort of patients with rheumatic disease
Zahrà Rahmé, Margherita Zen, Ilenia Anna Gennaio, Federico Arru, Filippo Vesentini, Noemi Merra, Luca Iaccarino, Marta Tonello, Alessandra Zambon, Andrea Doria (Italy)

P144 Pregnancy in connective tissue diseases: A 30 year follow-up study of 465 pregnancies from a Spanish monocentric registry
Cristiana Sieiro Santos, Paula Pérez García, José Ordas Martínez, Clara Moriano Morales, Carolina Álvarez Castro, Elvira Díez Álvarez (Spain)

P145 Circulating interferon-α levels are elevated during pregnancy in women with SLE who deliver infants that are small for gestational age, preterm and/or have low birth weight
Marit Stockfelt^{1,2}, Agnes Torell¹, Kaj Blennow³, Henrik Zetterberg^{3,4,5,6,7,8}, Tansim Akhter⁹, Dag Leonard¹⁰, Lars Rönnblom¹⁰, Sofia Pihl^{11,12}, Muna Saleh¹³, Christopher Sjöwall¹³, Helena Strevens¹⁴, Andreas Jönsen¹⁵, Anders A. Bengtsson¹⁵, Estelle Trysberg², Maria Majcuk Sennström¹⁶, Agneta Zickert¹⁷, Elisabet Svenungsson¹⁷, Iva Gunnarsson¹⁷, Bo Jacobsson^{18,19,20}, Anna-Carin Lundell¹, Anna Rudin^{1 (1-4,9-19)Sweden, 5-6UK, 7China, 8USA, 20Norway)}

P146 Low CD4+ T cell count is related to specific anti-nuclear antibodies, IFN α protein positivity and disease activity in systemic lupus erythematosus pregnancy
Agnes Torell^{1*}, Marit Stockfelt^{1,2}, Kaj Blennow^{3,4,5,6}, Henrik Zetterberg^{3,4,7,8,9,10}, Tansim Akhter¹¹, Dag Leonard¹², Lars Rönnblom¹², Sofia Pihl^{13,14}, Muna Saleh¹⁵, Christopher Sjöwall¹⁵, Helena Strevens¹⁶, Andreas Jönsen¹⁷, Anders A. Bengtsson¹⁷, Estelle Trysberg², Maria Majcuk Sennström¹⁸, Agneta Zickert¹⁹, Elisabet Svenungsson¹⁹, Iva Gunnarsson¹⁹, Johan Bylund²⁰, Bo Jacobsson^{21,22,23}, Anna Rudin¹, Anna-Carin Lundell¹ (¹⁻⁴:11-22Sweden, ⁵France, ⁶⁻⁹China, ⁷⁻⁸UK, ¹⁰USA, ²³Norway)

Treatment

P147 Is belimumab dose optimization possible in patients with systemic lupus erythematosus? Analysis of this therapeutic strategy in a large multicenter cohort of patients from Spanish rheumatology departments

Irene Altabás-González, José María Pego-Reigosa, Norman Jiménez, Andrea Hernández-Martín, Judit Font Urgelles, Ivette Casafont-Sole, Marta de la Rubia Navarro, José Andrés Román Ivorra, María Galindo Izquierdo, Tarek Salman Montes, Javier Narváez, Paola Vidal-Montal, María Jesús García-Villanueva, Sandra Garrote, Carlos Marras Fernández, María Piqueras García, Julia Martínez Barrio, Marina Sánchez Lucas, Josefina Cortés Hernández, Eleonora Penzo, Jaime Calvo Alen, Juan Ramón de Dios, Eva Tomero, Raúl Menor Almagro, Myriam Gandía Martínez, Jos. A. Gómez-Puerta, Beatriz Frade-Sosa, Consuelo Ramos Giraldez, Carmen Trapero Pérez, Elvira Díez Álvarez, Clara Moriano, Alejandro Muñoz Jiménez, Iñigo Rúa-Figueroa (Spain)

P148 Comparison of cyclophosphamide and rituximab in the treatment of severe systemic lupus erythematosus
Gergely Bodor, Martin Takács, László Kovács (Hungary)

P149 Clinical worsening in non-adherent belimumab treatment in SLE
Marta de la Rubia Navarro, Elena Grau García, M^a Jesús Cuellar Monreal, Iago Alcántara Álvarez, Inmaculada Chalmeta Verdejo, Hikmat Charia, Luis González Puig, Anderson Víctor Huaylla Quispe, José Ivorra Cortés, Samuel Leal, Isabel Martínez Cordellat, Laura Mas Sánchez, Pablo Francisco Muñoz Martínez, Rosa Negueroles Albuixech, José Eloy Oller Rodríguez, Daniel Ramos Castro, Carmen Riesco Bárcena, Alba Torrat Novés, Ernesto Tovar Sugrañes, Elvira Vicens Bernabeu, Belén Villanueva Mañes, Inés Cánovas Olmos, Carmen Nájera Herranz, José Andrés Román Ivorra (Spain)

P150 Temporal trends in treatment patterns in systemic lupus erythematosus in Sweden
Annica Dominicus¹, Arthur Mageau^{1,2}, Ngoc V. Nguyen¹, Elisabet Svenungsson³, Elizabeth V. Arkema¹ (¹⁻³Sweden, ²France)

P151 ActiLup - High intensity interval training and fatigue in systemic lupus erythematosus
Matthias Dreher, Sameer Petros, Sarah Engelhardt, Laura Geselle, Andreas Schwarting (Germany)

P152 Exploring global discrepancies in systemic lupus erythematosus treatment
Eman Elfar¹, Gagandeep Sukhija¹, Amelia Holloway¹, Sook Yan Lee¹, Elena Nikiphorou^{1,2}, Ioannis Parodi^{3,4}, Naveen R⁵, Jessica Day^{6,7,8}, Mrudula Joshi⁹, Sreoshi Saha¹⁰, Syahrul Sazliyana Shaharir¹¹, Wanruchada Katchamart¹², Phonpen Akawatcharangura Goo¹³, Lisa S Traboco¹⁴, Yi Ming Chen^{15,16}, Parikshit Sen¹⁷, James B. Lilleker^{18,19}, Arvind Nune²⁰, John D Pauling^{21,22}, Ai Lyn Tan^{23,24}, Nelly Ziade^{25,26}, Marcin Milchert²⁷, Abraham Edgar Gracia-Ramos²⁸, Carlo Vinicio Caballero-Urbe²⁹, COVAD Study Group Vikas Agarwal³⁰, Rohit Aggarwal³¹, Latika Gupta^{32,33}, Chris Wincup^{1,2} (^{1-2,18-24,32-33}UK, ³⁻⁴Sweden, ^{5,9,17,30}India, ⁶⁻⁸Australia, ¹⁰Bangladesh, ¹¹Kuala Lumpur, ¹²⁻¹³Thailand, ¹⁴Philippines, ¹⁵⁻¹⁶Taiwan, ²⁵⁻²⁶Lebanon, ²⁷Poland, ²⁸Mexico, ²⁹Colombia; ³¹USA)

P153 Real world experience with Belimumab in systemic lupus erythematosus patients in a Portuguese single center cohort
Raquel Faria, António Lamas, António Marinho, Carlos Vasconcelos (Portugal)

P154 Rilonecept use in lupus pericarditis
Andrea Fava, Michael Cammarata, Luigi Adamo (USA)

P155 Identifying a population of patients for intensive first-line therapy in SLE: A clinical and biomarker model to predict the need for intensive therapy
Porntip Intapiboon^{1,2}, Sabih Ul Hassan^{1,3}, Jack Arnold¹, Khaled Mahmoud¹, Edward M Vital^{1,3}, Md Yuzaiful Md Yusof^{1,3} (¹⁻³UK, ²Thailand)

P156 Recommendations of nonpharmacological management of SLE and SS: Assessing alignment with clinical care
Francesca Marchiori^{1,6}, Rita Schriemer^{2,3}, Els van den Ende³, Agnes Kocher⁴, Valentin Ritschl⁵, Birgit Barten⁶, Ilaria Galetti⁷, Rene Westhovens⁸, Oliver Distler⁹, Carina Bostrom¹⁰, Ioannis Parodis¹⁰ (¹⁻⁷⁻⁸Belgium, ²⁻³The Netherlands, ^{4,6-9}Switzerland, ⁵Austria, ¹⁰Sweden)

P157 Baricitinib for the treatment of Rhus Syndrome
Pablo Martínez Calabuig, Jorge Juan Fragío Gil, Roxana González Mazarío, Sara Moner Marín, Laura Salvador Maicas, Mireia Sanmartín Martínez, Amalia Rueda Cid, Juan José Lerma Garrido, Clara Molina Almela, Cristina Campos Fernández (Spain)

P158 Belimumab for the treatment of systemic lupus erythematosus in the Real World: A single center study
Pablo Martínez Calabuig, Jorge Juan Fragío Gil, Roxana González Mazarío, Sara Moner Marín, Laura Salvador Maicas, Mireia Sanmartín Martínez, Amalia Rueda Cid, Juan José Lerma Garrido, Clara Molina Almela, Cristina Campos Fernández (Spain)

P159 Severe infections in SLE patients: A descriptive analysis from a single centre
Giorgia Montozzi, S. Salvucci, R. Santangeli, L. Gamba, C. Cocco, P. Fioretti, L. Curina, Lucia Manfredi, G. Moroncini (Italy)

P160 Drug survival in SLE: Real world data from the Vienna Lupus Cohort
Daniel Mrak, Julia Pacher, Lena Reischmann, Peter Weber, Kastriot Kastrati, Leonhard X. Heinz, Daniel Aletaha, Michael Markus Bonelli, Helga Lechner-Radner (Austria)

- P161 Successful treatment of pulmonary hypertension and grade 3 lupus nephritis with triple combination treatment for pulmonary hypertension (Macitentan, Tadalafil, Selexipag) and cyclophosphamide**
 Anuoluwapo R. Oke, Khin Yein, Azeem Ahmed (UK)
- P162 Targeting TGF- β :BMP-7 ratio to improve prognosis in rheumatic disease: Treatment outcome in experimental myocarditis**
 Tracey Ollewagen, Carine Smith (South Africa)
- P163 Efficacy of deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, in musculoskeletal manifestations of systemic lupus erythematosus: A subanalysis of the phase 2 PAISLEY study**
 Marilyn Pike¹, Amit Saxena², Richard Furie³, Peter Nash⁴, Thomas Dörner⁵, Coburn Hobar⁶, Samantha Pomponi⁶, Ravi Koti^{7,6}, Subhashis Banerjee⁶, Thomas Wegman⁶, Joan Merrill⁸ (^{1-3:6}USA, ⁴Australia, ⁵Germany)
- P164 Rituximab intervention in management of thrombocytopenia in patients with systemic lupus erythematosus: A single center experience**
 Zeynep Toker Dincer, Yagmur Ersoy, Ogulcan Karali, Beste Acar, Talal Ammar, Serdal Ugurlu (Turkey)
- P165 Kinetics of mucocutaneous and musculoskeletal responses to deucravacitinib in patients with systemic lupus erythematosus (SLE) in the phase 2 PAISLEY trial**
 Ronald F. van Vollenhoven¹, Joseph F. Merola², Kathryn H. Dao³, Piotr Leszczynski⁴, Marilyn Pike⁵, Samantha Pomponi⁶, Coburn Hobar⁶, Matthew J. Colombo⁶, Ravi Koti⁷, Subhashis Banerjee⁶, Thomas Wegman⁶, Eric Morand⁸ (¹The Netherlands, ^{2-3:5-7}USA, ⁴Poland, ⁸Australia)

Late-breaking posters

- LBP1 Interim results of an open-label, multicentre, phase 1/2 study to assess YTB323 (rapcabtagene autoleucel), a CAR T-cell therapy, for severe refractory systemic lupus erythematosus**
 Josefina Cortés Hernández^{1,2}, Pere Barba^{2,3}, José María Álvaro-Gracia Álvaro⁴⁻⁶, Mi Kwon⁷⁻⁸, Julia Weinmann-Menke⁹, Eva Wagner-Drouet¹⁰, Ozana Fischer¹¹, Beata Kovacs¹¹, Frédérique Chaperon¹¹, David Pearson¹¹, Tiina Kirsilä¹¹, Chih-Yung Sean Lee¹², Clive Drakeford¹³, Peter Gergely¹¹, Giulio Cavalli¹¹, Tamas Shisha¹¹ (¹⁻⁸Spain, ⁹⁻¹⁰Germany, ¹¹Switzerland, ¹²USA, ¹³Ireland)
- LBP2 Development and validation of a patient-centered autoevaluation questionnaire in systemic lupus erythematosus: LUPIN**
 Marc Scherlinger¹, Jean Francois Kleinmann², Antonin Folliasson³, Marianne Riviere⁴, Raphaëlle Rybak⁴, Sabine Malivoir⁵, Jean-François Viillard⁶, Frédéric Renou⁷, Estibaliz Lazaro⁸, Christophe Richez⁸, Pascal Roblot⁹, Mathieu Puyade¹⁰, Clara Baverez¹¹, Arnaud Hot¹², Christophe Deligny¹³, Nicolas Baillet¹⁴, Daniel Wendling¹⁵, Julien Campagne¹⁶, Christian Agard¹⁷, Roland Jaussaud¹⁸, Thomas Moulinet¹⁹, Denis Wahl²⁰, Gilles Blaison²¹, Elisabeth Diot²², Nicole Ferreira-Maldent²³, Isabelle Marie²⁴, Nicolas Girszyn²⁴, Laurent Perard²⁵, Marc André²⁶, Pauline Orquevaux²⁷, Amelie Servettaz²⁸, François Chasset²⁹, Baptiste Hervier³⁰, Thierry Martin³¹, Cécile Fermont³², Emmanuelle David³³, Loïc Raffray³⁴, Ludovic Trefond³⁵, Perrine Smets³⁵, Julie Lescanff³⁶, Jacques-Eric Gottenberg³⁷, Xavier Mariette³⁸, Zahir Amoura⁵, Jean Sibilia³⁷ (^{1-6:8-12:15-38}France, ⁷Reunion Island, ¹³Martinique, ¹⁴Guadeloupe)
- LBP3 Comparative evaluation of ChatGPT and Google Bard as Artificial Intelligence-based tools together with expert validation in SLE patient's education**
 Abhibroto Karmakar, Ajit Singh, Anchal Chhabra, Shyna Madaan, Smita Prabhu, Rahul Maheshwari, Vinod Ravindran, Shankar Prasad, Uma Kumar, Subhradip Karmakar, Mukhyaprana M. Prabhu (India)
- LBP4 Pulmonary diseases found with thoracic ultrasound among incident systemic lupus erythematosus patients at a tertiary university hospital - A case series**
 Henrik Langkilde, Jesper Davidsen, Stefan Harders, Anne Voss (Denmark)
- LBP5 Real-life data of anifrolumab as a treatment for Systemic Lupus Erythematosus (SLE)**
 Laura Salvador Maicas, Jorge Juan Frago, Pablo Martínez Calabuig, Roxana González Mazarío, Mireia Lucía Sanmartín Martínez, Clara Molina Almela, Amalia Rueda Cid, Juan José Lerma Garrido, Cristina Campos Fernández (Spain)
- LBP6 Early access program experience of anifrolumab in systemic lupus erythematosus patients in a Portuguese single center cohort**
 Raquel Faria, Mariana Brandão, Fátima Farinha, António Marinho, Carlos Vasconcelos (Portugal)

SLEuro
EUROPEAN LUPUS SOCIETY



15th European Lupus Meeting

SAVE THE DATE

Lisbon, Portugal
4 - 7 March 2026



Scientific Information





Download the LUPUS 2024 App!

Available in the App store and the Google Play store



Scan to download



App

Download the Lupus 2024 App on your mobile phone and create your personal profile!
Have the most relevant and up-to-date information at hand and bookmark your favourite sessions.

Publication of the Abstracts

The abstracts of the invited, oral and poster presentations will be published online in the journal Lupus Science & Medicine, which is the official journal of Lupus 2024.

Lupus Science & Medicine® is a global, peer-reviewed, open access lupus journal from LFA, publishing papers on all aspects of lupus and related diseases.

Impact factor: 4.687

LUPUS SCIENCE & MEDICINE™

Accreditation & Certificates

UEMS accreditation

The 14th European Lupus Meeting has been granted 13.5 European CME Credits. In order to obtain these credits, participants are requested to

- Sign the attendance list each day (lists available at the registration desk, level 0)
- Fill out the questionnaire that will be sent at the end of the Meeting.



Belgian accreditation

An accreditation application has been submitted to the RIZIV/INAMI.

In order to obtain Belgian accreditation points, participants are requested to

- Bring their ID to the Meeting
- Confirm their attendance by inserting their ID into an e-ID reader on each day.



Certificate of Attendance

All participants will receive a Certificate of Attendance by email after the 14th Lupus Meeting. This certificate confirms your participation, but does not confirm Belgian or UEMS accreditation (see higher).

Invited and Oral Presentations

Presenters are requested to upload their PPT presentation in the Speakers' Corner, located next to the registration desk on level 0 at the latest 2 hours before the start of their talk.

Presentations from laptops are not allowed.

Speaking time is as follows:

A talk of 25 minutes in the programme consists of 22 minutes speaking time and 3 minutes for Q&A.

A talk of 20 minutes in the programme consists of 17 minutes speaking time and 3 minutes for Q&A.

A talk of 15 minutes in the programme consists of 12 minutes speaking time and 3 minutes for Q&A.

A talk of 10 minutes in the programme consists of 8 minutes speaking time and 2 minutes for Q&A.

Talks in sponsored sessions may differ from the above instructions.

Speakers must adhere to the time allotted for their talk and must divulge any conflict of interest.

Poster Presentations

Poster dimensions

The poster dimensions are: max width: 90 cm & max height: 120-150 cm (= PORTRAIT position).

Installation of the posters

Tuesday 19 March between 17.00 and 20.00 hrs

Wednesday 20 March, between 08.00 and 11.00 hrs

Removal of the posters

Friday 22 March, between 13.00 and 14.00 hrs

Fixing material will be available on level 3 (2nd balcony), see floor plan on page 6.

Poster Sessions

There are 2 poster sessions, one on Wednesday and one on Thursday.

Poster Session 1

The presenters of the posters P1 through P80 are requested to be present at their posters for Q&A from 12.45 until 13.30 hrs on Wednesday 20 March.

Poster Session 2

The presenters of the posters P81 through P165 and LBP1 through LBP6 are requested to be present at their posters for Q&A from 12.45 until 13.30 hrs on Thursday 21 March.

Guidelines for non-MDs

To be in accordance with EFPIA regulations, non-MDs are not allowed to visit the exhibition.

Non-MDs are therefore kindly requested to:

- Use the elevator to go to the **Concert Hall**: when exiting the elevator proceed immediately to the left
- Use the stairs or the sloping access and go right immediately to access the **Chamber Music Room**
- Use the stairs or the sloping access and on arrival in the Foyer level 1 go straight ahead to **Studio 1** or the **Green Room**
- Use the elevator to go to level 2 (1st balcony) for all **catering** moments (Walking Dinner on Tuesday, the lunches and coffee breaks on Wednesday, Thursday and Friday)
- Use the elevator to go to level 3, to view the **posters** and to go to the **Angel Room**

SLEuro Secretariat and General Assembly

SLEuro Secretariat will have a desk in the registration area on level 0.

The **General Assembly** of the European Lupus Society will take place in the Chamber Music Room at 07.45 hrs on Friday 22 March. The General Assembly is open to all SLEuro members in good standing. Your membership status will be checked before the start of the General Assembly.

Fishbowl sessions

On Thursday 21 March, interactive sessions called ‘Fishbowls’ will be organised throughout the meeting in 4 different areas.

Delegates are invited to choose their favorite topic, see page 30.

What is a fishbowl session?

The fishbowl activity is a simple but effective method used to manage group discussion.

The general idea is that rather than a large group having an open discussion, a smaller group of 3 to 6 participants is seated in an inner circle to discuss a specific topic while the rest of the participants sit in an outer circle observing the inner discussants. There is always one chair left empty in the inner circle. This chair is available for someone from the observing plenum to take a seat and to make a statement or ask a question and thus to take an active part in the discussion. There is one moderator who will frame the opening of the conversation and then let go. Moderating is supposed to be kept at a minimum.

Fishbowl - the essence

- Discussion in inner circle
- Observing and thinking in outer circle
- Impulse from person on “empty chair”
- Moderator: guides through questions, reflections and summaries
- Recorder: summarizes results



Rules

- 5 participants + “empty chair” in inner circle
- Discussion only in inner circle
- Only one discussant in the inner circle talks at a time
- Each statement should relate to the previous contribution
- The empty chair in the inner circle enables the plenum to actively participate in the discussion by asking a question or expressing an opinion
- Members of the plenum on the free chair have immediate right to speak. After their statement, the members leave the inner circle and return to the outer circle
- The plenum observes, takes notes and participates actively on empty chair
- The moderator opens and moderates the discussion and watches the compliance with the rules
- The moderator intervenes only if necessary



Sponsored Sessions





FIND AN ONGOING BMS CLINICAL TRIAL NEAR YOU

SCAN ME



SCAN ME



Phase 3: Two Studies to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active **Systemic Lupus Erythematosus** (SLE)

SCAN ME



Phase 3: A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults with Active **Sjögren's Syndrome** (POETYK SJS-1)

SCAN ME



Phase 2: A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With **Active Discoid and/or Subacute Cutaneous Lupus Erythematosus** (DLE/SCLE)

SCAN ME



Phase 2: A Study Evaluating the Efficacy and Safety of Afimeteran Compared With Placebo in Participants With **Active Systemic Lupus Erythematosus** (SLE)

SCAN ME



Phase 1: Study of CD19-targeted NEX-T CAR T Cells in Participants with Severe, Refractory **Systemic Lupus Erythematosus** (SLE)

SCAN ME



Phase 1: A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of **Lupus**

Thank you to all of the patients, doctors, and caregivers who have participated in 20+ years of BMS rheumatology research!

For more information about these clinical trials:

Email: Clinical.Trials@bms.com

Visit: bmsstudyconnect.com

Visit our booth

For more information on our clinical trials or to learn more about BMS's commitment to rheumatology



Please join us for the following session

Meet the Expert

Wednesday, 20 March from 8:00 - 9:00 AM
Chamber Music Room



Please join us for the following session

Advances in Lupus: Spotlight on a Novel Therapeutic Approach

Professor Ronald van Vollenhoven
Friday, 22 March from 11:00 - 11:30 AM
Concert Hall



©2024 Bristol-Myers Squibb Company





Industry-Sponsored Breakfast Meeting

Chamber Music Room

08.00 – 09.00 hrs

Introduction

Rational for treating SLE patients with CAR T cell therapy

Outlining the CAR T patient Journey

Challenges and Opportunities related to CAR T cell treatment

Discussion

Speaker:

Mario Andres Sanchez Salinas, Vall d'Hebron Hospital, Barcelona, Spain

Moderator:

Christopher Sjöwall, Linköping University, Linköping, Sweden



Industry-Sponsored Symposium

Concert Hall

Advancing lupus care: early intervention to reduce the risk of organ damage progression

Chair: Marta Mosca, Pisa (IT)

13.30 **Why should we consider using biologics earlier for non-renal SLE?**

13.55 **How can we preserve kidney function?**

14.20 **Q&A session**

14.25 **Summary and next steps**

Faculty:

Marta Mosca, University of Pisa, Italy

Alfred Kim, Washington University School of Medicine, USA

Ioannis Parodis, Karolinska University Hospital, Solna, Sweden

Join GSK at the 14th European Lupus Meeting 2024

GSK is proud to be sponsoring a satellite symposium and fishbowl sessions at the European Lupus Meeting 2024. We look forward to engaging with you in important discussions about the management of SLE.

SATELLITE SYMPOSIUM

Advancing lupus care: early intervention to reduce the risk of organ damage progression

🕒 March 20, 13:30 – 14:30 CET
📍 Join us in the Concert Hall

Marta Mosca, MD, PhD
University of Pisa, Italy

Alfred Kim, MD, PhD
Washington University School of Medicine, US

Ioannis Parodis, MD, PhD
Karolinska University Hospital, Sweden

In this symposium, global experts will share their insights in advancing care for those living with lupus. Professor Marta Mosca, Associate Professor Alfred Kim, and Associate Professor Ioannis Parodis will discuss ways to reduce the risk of organ damage progression, supported by the latest recommendations, guidelines, and real-world evidence. They will discuss different patient profiles to identify those who are suitable for starting a biologic. Please join us and be part of the conversation to advance lupus care in daily practice.

This is an industry symposium sponsored and organized by GSK at the European Lupus Meeting 2024. GSK products will be discussed.

Join us at our booth

FISHBOWL SESSIONS

When is the window of opportunity for disease modification in lupus?

🕒 March 21, 16:30 – 17:15 CET
📍 Join us in the Chamber Music Room

George Bertias, MD, PhD
University of Crete, Greece

Mariele Gatto, MD, PhD
Mauriziano Hospital, University of Turin, Italy

Ana Malvar, MD
Hospital Fernandez, Argentina

Francesca Marchiori, MS
Lupus Europe Patient Advisory Network (PAN) member

Don't miss your chance to be part of the conversation at the GSK-sponsored fishbowls. You can bring your own insights and questions to discussions about key topics in the management of systemic lupus erythematosus and engage with leading experts. We look forward to welcoming you to these fishbowl sessions.

Glucocorticoids: tapering to zero?

🕒 March 21, 17:15 – 18:00 CET
📍 Join us in the Chamber Music Room

Maria Tektonidou, MD, PhD
National and Kapodistrian University of Athens, Greece

Margherita Zen, MD, PhD
University Hospital of Padova, Italy

Luís Sousa Inês, MD, PhD
Coimbra Hospital and University Center (CHUC), Portugal

Jeanette Andersen, MSc
President, Lupus Europe

Aiming for new treatment goals in SLE care

Thursday 21 March 2024; 08:00–09:00 CET
Studio 1 – Level 1

Join Ioannis Parodis and Marta Mosca as they discuss the importance of setting treatment goals in SLE, as well as reflecting on how incorporating the patient perspective into targeted treatment strategies can help to transform long-term SLE management.

What do the treatment goals of remission and LLDAS mean for long-term patient outcomes?

Professor Ioannis Parodis (Chair) in conversation with Professor Marta Mosca

What do advancements in the SLE treatment landscape mean for achieving our treatment goals?

Professor Marta Mosca

How do we make our aspirational treatment goals a reality in clinical practice?

Professor Ioannis Parodis (Chair) in conversation with Professor Marta Mosca

Q&A with the experts

AstraZeneca 

Industry-Sponsored Breakfast Meeting

Studio 1

Aiming for new treatment goals in SLE care

Chair: Ioannis Parodis, Solna (SE)

- 08.00 **Opening remarks**
Ioannis Parodis, Solna (SE)
- 08.10 **What do the treatment goals of remission and LLDAS mean for long-term patient outcomes?**
Ioannis Parodis, Solna (SE) and Marta Mosca, Pisa (IT)
- 08.20 **What do advancements in the SLE treatment landscape mean for achieving our treatment goals?**
Marta Mosca, Pisa (IT)
- 08.35 **How do we make our aspirational treatment goals a reality in clinical practice?**
Ioannis Parodis, Solna (SE) and Marta Mosca, Pisa (IT)
- 08.50 **Q&A, summary and close**
All

Faculty:

Marta Mosca, University of Pisa, Italy
Ioannis Parodis, Karolinska Institutet, Solna, Sweden

SAVE THE DATE!

14th European Lupus Meeting (SLEuro)

Toll-like receptors take centre stage in lupus immune dysregulation

Merck-sponsored Scientific Meeting

Thursday, 21 March 2024, 08:00–09:00 AM CET

Chamber Music Room – Concertgebouw venue, Bruges, Belgium

Welcome coffee and pastries served from
07:45 AM CET – Foyer, Chamber Music Room

**Welcome and opening:
Turning a spotlight on
lupus disease and current
treatment challenges**



Eric Morand (Chair)

Monash University,
Melbourne, Australia

**Lupus pathophysiology and the
role of toll-like receptors**



Carola Vinuesa

The Francis Crick Institute,
London, UK

Current approaches to CLE



Miriam Wittmann

Johannes Gutenberg University
Mainz, Mainz, Germany

TLR7/8 inhibition in SLE and CLE



Eric Morand

Q&A



Facilitated by Eric Morand

Speakers



Eric Morand



Carola Vinuesa



Miriam Wittmann

Sponsored Session - Thursday 21 March



MERCK

Industry-Sponsored Breakfast Meeting

Chamber Music Room

08.00 – 09.00 hrs

Toll-Like Receptors take centre stage in lupus immune dysregulation

Chair: Eric Morand, Melbourne (AU)

Session 1 Welcome and opening: Turning a spotlight on lupus disease and current treatment challenges

Eric Morand, Melbourne (AU)

Session 2 Lupus pathophysiology and the role of Toll-Like Receptors

Carola Vinuesa, London (UK)

Session 3 Current approaches to CLE

Miriam Wittmann, Mainz (DE)

Session 4 TLR7/8 inhibition in SLE and CLE

Eric Morand, Melbourne (AU)

Session 5 Q&A

Facilitator: Eric Morand, Melbourne (AU)

Faculty:

Eric Morand, Monash University, Melbourne, Australia

Carola Vinuesa, The Francis Crick Institute, London, UK

Miriam Wittmann, Johannes Gutenberg University Mainz, Mainz, Germany

CLE, cutaneous lupus erythematosus; SLE, systemic lupus erythematosus; TLR, toll-like receptor

© 2024 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved

GL-M5049-00033 | February 2024

MERCK

WWW.LUPUS24.BE



Industry-Sponsored Symposium

Concert Hall

Reshaping SLE care:**is remission now possible for the many, not just the few?**

Co-chairs: Zahir Amoura, Paris (FR) and Ian Bruce, Manchester (UK)

13.30 **How well are we doing, and why is there a need to change our approach to SLE care?**

Ian Bruce, Manchester (UK) and Zahir Amoura, Paris (FR)

13.50 **Time matters: why early and sustained disease control in SLE is key**

Julia Weinmann-Menke, Mainz (DE)

14.05 **Reaching for remission in SLE: what is now possible?**

José Álvaro-Gracia, Madrid (ES)

14.20 **Q&A and close**

All

Faculty:

José Álvaro-Gracia, Complutense University, Madrid, Spain

Zahir Amoura, Pitié-Salpêtrière Hospital, Paris, France

Ian Bruce, University of Manchester, UK

Julia Weinmann-Menke, Johannes Gutenberg University Mainz, Germany



Industry-Sponsored Fishbowls

Chamber Music Room

16.30 – 17.15

I When is the window of opportunity for disease modification in Lupus?

Chair: George Bertias, Heraklion (GR)

Discussants: Mariele Gatto, Torino (IT), Ana Malvar, Buenos Aires (AR),
Francesca Marchiori, Lupus Europe (IT)

17.15 – 18.00

V Glucocorticoids: Tapering to zero?

Chair: Maria Tektonidou, Athens (GR)

Discussants: Margherita Zen, Padova (IT), Luís Sousa Inês, Coimbra (PT),
Jeanette Andersen, Lupus Europe (DK)

INDUSTRY SYMPOSIUM AT Lupus 2024 Meeting



Future perspectives in lupus nephritis

Friday 22nd March, 8.45-9.15 CET
Concert Hall

Scientific Programme

Timing	Presentation title	Speakers
8:45 – 8:47	Welcome and introduction	Liz Lightstone
8:47 – 8:57	Management of lupus nephritis: current perspectives and future directions	Ioannis Parodis
8:57 – 9:09	Practical management of lupus nephritis: a case presentation	Liz Lightstone and Ioannis Parodis
9:09 – 9:15	Q&A	Liz Lightstone and Ioannis Parodis



**Professor
Liz Lightstone**

Imperial College London,
UK



**Associate Professor
Ioannis Parodis**

Karolinska University Hospital,
Stockholm, Sweden

RocheNephrology

INSPIRED BY *Many*

This symposium is not intended for physicians practicing in the US

Veeva number: M-XX-00016240

Date of preparation: February 2024

Sponsored Session - Friday 22 March



Industry-Sponsored Symposium

Concert Hall

Future perspectives in lupus nephritis

- 08.45 **Welcome and Introduction**
Liz Lightstone, London (UK)
- 08.47 **Management of lupus nephritis: Current perspectives and future directions**
Ioannis Parodis, Solna (SE)
- 08.57 **Practical management of lupus nephritis: A case presentation**
Liz Lightstone, London (UK) and Ioannis Parodis, Solna (SE)
- 09.09 **Q&A**
Liz Lightstone, London (UK) and Ioannis Parodis, Solna (SE)



Sponsored Session - Friday 22 March



Industry-Sponsored Symposium

Concert Hall

Advances in Lupus: Spotlight on a novel therapeutic approach

- 11.00 **JAK Family Signal Mediators**
Ronald van Vollenhoven, Amsterdam (NL)
- 11.05 **Cytokine Pathway Inhibition in SLE**
Ronald van Vollenhoven, Amsterdam (NL)
- 11.13 **Emerging Clinical Trial Data**
Ronald van Vollenhoven, Amsterdam (NL)
- 11.25 **Audience Q&A**


Faculty:

Ronald van Vollenhoven, Amsterdam University Medical Centers; Chair, EULAR Research Committee; Editor-in-Chief, Lupus Science & Medicine; Amsterdam, the Netherlands



Sponsors & Exhibitors





Exhibitors

- A GSK
- B AstraZeneca
- C Bristol Myers Squibb
- D Roche
- E Merck
- 1 Kyverna Therapeutics
- 3 Otsuka Pharmaceutical Europe Ltd
- 4 QuidelOrtho
- 5 Biogen
- 6 The Lupus Academy
- 7 Novartis
- 8 AbbVie
- 9 Otsuka Pharma Scandinavia AB
- 10 Lupus Forum

Diamond Sponsor



Platinum Sponsor



White Gold Sponsor



Gold Sponsor



Silver Sponsor



Bronze Sponsors



High throughput Lupus screening

Fast results for Lupus anticoagulant and APTT reagents on CN-Series systems



- ✓ Up to 450 tests per hour and an on-board stability of > 3 days (LA) and > 4 days (APTT)
- ✓ Sysmex CN-Series offers automated cross-mixing function to exclude factor deficiencies
- ✓ State-of-the-art reagents with different characteristics available meeting your specific needs and supporting ISTH guideline* recommended workflow for the detection of Lupus anticoagulant
 - **DRVTT:** Lupus anticoagulant screen and confirm reagents
 - **APTT:** LA-sensitive and -insensitive APTT reagent with different activators



Get more information on
www.sysmex-europe.com/haemostasis



Social Programme



Tuesday 19 March**19.45 hrs – Walking Dinner**

Participants, sponsors and exhibitors are cordially invited to the Opening Session followed by a **Walking Dinner**. This Walking Dinner takes place in the Foyer on level 1 and the 1st Balcony on level 2 of Concertgebouw.

The Walking Dinner is included in the registration fee. Pre-registration, however, was requested. (Please check the back of your badge: if booked, it will be listed there)

Wednesday 20 March**18.00 hrs - Guided City Tour**

Experienced city guides will take you on a fascinating walking tour through Bruges' rich history.

The city tour will start at 18.00 hrs and will end on the Burg Square, one of the main squares in Bruges, surrounded by historic buildings including the Basilica of the Holy Blood.

We propose to meet outside the main entrance at 18.00 hrs.

Duration of the tour: 1.5 hrs

The guided city tour is not included in the registration fee. Separate registration and payment is required.

(Please check the back of your badge: if booked, it will be listed there)

Thursday 21 March**19.30 hrs - Gala Dinner at Brewery 'De Halve Maan'**

The Gala Dinner will take place at Brewery 'De Halve Maan', located in the heart of the city, at a mere 5 to 10 minutes' walking distance from most of the hotels.

The evening will consist of two parts.

19.30 hrs – Guided Visit of the Brewery

Experienced guides will introduce you to the world of hop and malt in this state-of-the-art brewing house.

20.30 hrs – Gala Dinner

After a tempting culinary feast with various beers carefully pairing with the menu, a select few will learn to pull their own beer under the guidance of a beer sommelier during a Beer Masterclass.

Important notes During the tour of our brewery, please be aware that there are 220 steps to navigate. Some of these steps can be steep, so we strongly recommend wearing appropriate footwear for your comfort and safety.

For participants who may have difficulty walking, we regret to inform you that the tour may not be suitable. However, you are welcome to join the group at 20.30 hrs. We apologize for any inconvenience this may cause. The brewery is located in a centuries-old building without modern facilities. Thank you for your understanding.

The Gala Dinner is not included in the registration fee. Separate registration and payment is required.

(Please check the back of your badge: if booked, it will be listed there)



Your best life
is our life's work.

For ten years, we've dedicated ourselves to making a difference in people's lives. Creating medicines and solutions that help patients, communities, and our world. We find answers that make lives better. And we won't stop until we've raised the standard of treatment for all.

abbvie

abbvie.com

ABBY-AA-03364-E v1.0 | Approved February 2024



Registration Information



Registration fees

As of 16/03

Member SLEuro	€ 675,00
Non-Member	€ 725,00
Student/Trainee *	€ 375,00
Health Professional Non-MD/Researcher*	€ 375,00
Patient	
Full Period	€ 150,00
1 Day – 20 March	€ 50,00
1 Day – 21 March	€ 50,00
2 Days – 20 & 21 March	€ 95,00

All prices include 21% VAT.

*Proof of status is required to sign up at this rate.

The registration fees include

- Participation in the scientific programme
- Walking Dinner on Tuesday
- Coffee breaks and lunches as indicated in the programme

Payment

On-site payments are to be made cash (in Euro) or by credit card (Visa and Mastercard).

Cancellations

Participants cancelling their registration before 15 February 2024 will receive a full refund, less € 150,00 administration costs. There will be no refunds for cancellations received after this date.


Cancellations must be confirmed in writing to arielle@medicongress.com. All refunds will be processed after the Meeting.

Guidelines for non-MDs

To be in accordance with EFPIA regulations, non-MDs are not allowed to visit the exhibition.

Non-MDs are therefore kindly requested to:

- Use the elevator to go to the **Concert Hall**: when exiting the elevator proceed immediately to the left
- Use the stairs or the sloping access and go right immediately to access the **Chamber Music Room**
- Use the stairs or the sloping access and on arrival in the Foyer level 1 go straight ahead to **Studio 1** or the **Green Room**
- Use the elevator to go to level 2 (1st balcony) for all **catering** moments (Walking Dinner on Tuesday, the lunches and coffee breaks on Wednesday, Thursday and Friday)
- Use the elevator to go to level 3, to view the **posters** and to go to the **Angel Room**



where
science meets **humanity**™

Visit Biogen at Booth #5

As part of our long-standing efforts in neuroimmunology, we aspire to utilize our deep expertise in multiple sclerosis (MS), our knowledge of immunological pathways, and our scientific and development synergies to positively impact the lives of people living with serious autoimmune diseases such as lupus.



General Information



Novartis is committed to Immunology

Visit us in the exhibition area.



General Information

Venue

Concertgebouw

't Zand 34
8000 Bruges, Belgium
www.concertgebouw.be/en

Dates

Tuesday 19 March - Friday 22 March

Language

The official meeting language is English. There will be no simultaneous translation.

Registration Desk

The registration desk is located on the ground floor. The opening hours are:

Tuesday 19 March	16.00 – 22.00 hrs
Wednesday 20 March	07.00 – 18.00 hrs
Thursday 21 March	07.30 – 18.00 hrs
Friday 22 March	07.30 – 13.30 hrs

Information Desk

An information desk is located in the Foyer on level 1. The opening hours are:

Wednesday 20 March	10.00 – 16.30 hrs
Thursday 21 March	10.00 – 16.30 hrs
Friday 22 March	10.00 – 13.30 hrs

Exhibition

An exhibition takes place in the Foyer of level 1. The exhibition is not accessible for non-MDs.

Catering on level 1 and 2

For your convenience, all catering services, including the Walking Dinner on Tuesday, as well as lunches and coffee breaks, will be available on both level 1 (Foyer) and level 2 (1st Balcony).

While the Foyer may experience high traffic at times, we recommend that participants take their breaks on level 2 in a more relaxed setting.

As non-MDs are not allowed to visit the exhibition, they are kindly asked to take their lunches and coffee breaks exclusively on level 2.



Reshaping SLE care: is remission now possible for the many, not just the few?

**Thursday 21 March 2024; 13:30-14:30 CET
Concert Hall - Level 1**

Join the expert panel as they explore the importance of remission as a primary goal in SLE and reflect on their real-world clinical experience to outline strategies for achieving early and sustained disease control.

How well are we doing, and why is there a need to change our approach to SLE care? (Co-chairs)

Professor Zahir Amoura

Professor Ian Bruce

Time matters: why early and sustained disease control in SLE is key

Professor Julia Weinmann-Menke

Reaching for remission in SLE: what is now possible?

Professor José Álvaro-Gracia

Q&A and close

This symposium is organised and funded by AstraZeneca. AstraZeneca products will be discussed. Prescribing information will be available at the meeting and can also be found on the AstraZeneca booth. Veeva ID: BE-3405; Date of preparation: February 2024



We are proud to be the Diamond sponsor of the 14th European Lupus Meeting 2024

Join us at one of our sessions:

SATELLITE SYMPOSIUM

Advancing lupus care: early intervention to reduce the risk of organ damage progression

🕒 March 20, 13:30 – 14:30 CET

📍 Join us in the Concert Hall

FISHBOWL SESSIONS

When is the window of opportunity for disease modification in lupus?

🕒 March 21, 16:30 – 17:15 CET

📍 Join us in the Chamber Music Room

Glucocorticoids: tapering to zero?

🕒 March 21, 17:15 – 18:00 CET

📍 Join us in the Chamber Music Room

These are GSK-sponsored and organized sessions at European Lupus Meeting 2024. These events will be available to healthcare professionals only, who are registered delegates of the European Lupus Meeting 2024. GSK products will be discussed at the satellite symposium.

GSK is at the forefront of SLE care

We are continuously exploring new treatment options and building on a strong foundation of successful clinical studies to find new ways to help patients with lupus. In partnership with patients, advocates and physicians, we are committed to improving the lives of those affected by this chronic disease.